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The objective of this Master project was to evaluate a series of chalcone 
analogs bearing hydroxy, fluorine and/or methoxy substituents for their 
potential anti-invasive activities against breast carcinoma cells. Chalcones are 
a class of compounds bearing a 1,3-diphenyl-2-propen-1-one structural 
backbone and have been reported to possess anti-inflammatory, anti-cancer, 
antioxidant and anti-infectious effects. Breast cancer tumors, characterized by 
their highly invasive and metastatic phenotypes, have resulted in high 
mortalities among females. This study started with the evaluation of the 
cytotoxicity profiles of the chalcone analogs in MDA-MB-231 and MCF-7 
breast carcinoma cells, followed by selection of relatively non-cytotoxic doses 
(5 and 10 μM) for subsequent assessment of their effects on MMP-9 
expression and gelatinolytic activity. Hydroxylated chalcone analogs CC1 and 
CC3, as well as their respective methoxylated counterpart analog CC7 and 
CC9, were found to possess potent suppressive effects on MMP-9. The 
down-regulation of MMP-9 at transcriptional level by chalcones was found to 
be mediated at least in part through inhibition of the NF-κB signaling pathway. 
Taken together, the findings presented in this project uncovered hydroxylated 
and methoxylated chalcones exhibiting anti-invasive properties against breast 
carcinoma cells, and exposed the NF-κB signaling pathway as a molecular 
target of chalcones. Therefore, it warrants further development of this class of 
 vii 
 
compounds for applications in anti-invasive and anti-metastatic cancer 
therapies.     
 viii 
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Chapter 1: Introduction 
1.1 Chalcone analogs and their biological activities 
Chalcones, regarded as the precursors of flavonoids, are natural products 
widely distributed in fruits, vegetables, spices, tea and soy (Di Carlo et al., 
1999). The chemical structure of chalcone (1,3-diphenyl-2-propen-1-one) 
consists of two aromatic rings joined by a propenyl ketone system (Table 1 in 
Section 1.5). The α/β-unsaturated ketone moiety has been reported to play an 
important role in the biological activities observed (Ni et al., 2004). The 
biological activities of naturally occurring and synthetic chalcones are widely 
ranging, including anti-tumor, anti-inflammatory, anti-infectious, antioxidant 
and anti-hyperglycemic effects (Batovska and Todorova, 2010; Nowakowska, 
2007).  
 




















The anti-tumor activity may result from cytotoxic and/or chemopreventive 
effects. To date, a number of studies have revealed that cytotoxicities of 
chalcones can be attributed to several activities, including inhibition of 
angiogenesis (Nam et al., 2003), interference with p53-MDM2 interaction 
(Kumar et al., 2003; Stoll et al., 2001), induction of apoptosis (De Vincenzo et 
al., 2000; Saydam et al., 2003), antimitotic activity (Edwards et al., 1990) or 
mitochondrial uncoupling (Sabzevari et al., 2004). Chalcones’ 
chemopreventive properties may be attributed to their anti-inflammatory, 
antioxidant and anti-invasive properties (Surh and Chun, 2007).  
 
Angiogenesis is the proliferation of a network of new blood vessels from the 
pre-existing ones. The angiogenic ability of endothelial cells (EC) in blood 




healing and repair. Upon abnormal stimulation under disordered conditions, 
angiogenesis may also supply nutrients and oxygen for cancerous growth and 
therefore serves as the key step in tumor growth, invasion and metastasis 
(Mojzis et al., 2008). Chalcone analogs have been reported of being cytotoxic 
selectively towards human umbilical vein endothelial cells (HUVEC), which 
are critical cellular components for angiogenesis (Nam et al., 2003). 
Chalcones also possess inhibitory effects on the expression of vascular 
endothelial growth factor (VEGF), one of the important endogenous positive 
mediators of angiogenesis (Dell'Eva et al., 2007). Mouse double minute 2 
(MDM2) is an oncoprotein which can bind to the transactivation domain of 
tumor suppressor protein p53 and inhibit its function. Overexpression of 
MDM2 has been discovered in many tumor types (Juven-Gershon and Oren, 
1999; Oliner et al., 1992). Chalcones with carboxylic acid substituents are able 
to bind to the tryptophan pocket of the p53 binding site of MDM2 oncogenes. 
The binding promotes dissociation of the p53/MDM2 complex, leading to 
disregulation of the cell cycle (Stoll et al., 2001). Induction of apoptosis in 
tumor cells has been regarded as another mechanism of the cytotoxic activity 
of anti-tumor compounds. Several chalcones have been discovered to induce 
apoptosis in human neuroblastoma IMR-32 and leukemia Jurkat cells (Tabata 
et al., 2005), as well as to block cell cycle in the G2/M phase in human breast 
carcinoma MDA-MB-231 and MCF-7 cells (Hsu et al., 2006). Chalcones may 




potential antimitotic agents (Ducki, 2009). Furthermore, chalcones have been 
reported to suppress adenosine triphosphate (ATP) production by uncoupling 
oxidative phosphorylation, leading to energy consumption without ATP 
production and thereby exhibiting mitochondrial toxicity (Ravanel, 1986; 
Ravanel et al., 1980).     
 
Numerous studies have regarded chalcones as chemopreventive agents as well. 
Chemoprevention means the intervention of non-toxic natural or synthetic 
chemicals in multiple stages of cancer (Surh and Chun, 2007), among which, 
inflammation plays important roles in various aspects in carcinogenesis. 
Chronic inflammation contributes to the pathologic basis for malignancies in 
human. Major mediators linking inflammation and cancer are tumor necrosis 
factor-alpha (TNF-α), interleukin 6 (IL-6), cyclooxygenase 2 (COX-2), 
prostaglandin E2 (PGE2), prostanoid (EP 1-4) receptors, nitric oxide synthase 
(iNOS) and NO. Previous research have depicted chalcones’ inhibitory effect 
on NO production, which contribute to their anti-inflammatory effects 
(Gutteridge and Halliwell, 1992). Sustained inflammation may activate 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), which 
mediate DNA damage by causing the activation of oncogenes such as ras 
and/or inactivation of tumor suppressor genes such as p53 (Gutteridge and 
Halliwell, 1992; Kundu and Surh, 2008). Oxidative stress is also involved in 




ROS are generated by pro-oxidative stimuli and responsible for the mediation 
of damages to DNA, proteins and lipids. Usage of antioxidant agents therefore 
could be another choice of chemoprevention. As one of the important 
mechanisms of antioxidant drugs is to inhibit the formation of ROS or 
free-radicals, several chalcones have been reported as free-radical scavengers 
and exploited for use as antioxidants (Fuchs-Tarlovsky, 2012). Through 
induction of phase II detoxification of carcinogenic species, many 
chemopreventive agents exert antioxidant functions so as to prevent oncogenic 
insult-induced genotoxic damage. Phase II detoxification enzymes include 
glutathione S-transferase (GST), glutathione peroxidase (GPx), UDP 
glucuronosyl transferase (UGT), NADPH:quinone oxidoreductase-1 (NQO1), 
heme oxygenase-1 (HO-1) and glutamate Cysteine ligase (GCL) (Lee and 
Surh, 2005). The inductions of transcription of phase II enzymes are regulated 
by the activation of the promoter sequence antioxidant-response element 
(ARE) found at 5’ end of these genes. Activation of the ARE promoter 
sequence is in turn mediated by nuclear transcription factor erythroid 2p45 
(NF-E2)-related factor 2 (Nrf2), which is sequestered in cytoplasm by 
Kelch-like ECH-associated protein 1 (Keap 1). Chalcones have been reported 
to induce the activities of phase II detoxification enzymes such as GST, UGT, 
as well as NQO1 and epoxide hydrolase via activation of the Nrf2-Keap1 
signaling pathway, which contribute to cytoprotection against carcinogenesis 




McLellan, 1999). Inhibition of tumor invasion has also been regarded as a 
major contributor to chemoprevention in cancer therapy. The detailed 
introduction of anti-invasive properties can be found later in Section 1.3 and 
1.4 in this Chapter.  
1.1.1 Naturally occurring chalcones  
Several naturally occurring chalcones isolated from plants have been approved 
for investigation in clinical trials for various therapeutic purposes, such as 
metochalcone for anti-choleretic effect, sofalcone for anti-ulcer effect, 
Ro-09-0415 for controlling rhinovirus infection and hesperidin 
methyl-chalcone for modulation of chronic venous lymphatic insufficiency 
(Sahu et al., 2012).  
 
Numerous chalcones have been reported to exert cytotoxicities to various 
tumor cells, which suggest their promising potential for use in cancer 
chemotherapy. For example, main components derricin (Figure1.1 A) and 
lonchocarpin (Figure1.1 B) found in the hexane extract obtained from the 
roots of Lonchocarpus sericeus have demonstrated cytotoxicity against CEM 
leukemia cells (Cunha et al., 2003; Sebti et al., 2001). In a study conducted by 
National Cancer Institute (NCI) (Boyd and Paull, 1995), the patterns of 
cytotoxicities of naturally occurring chalcone calythropsin (Figure 1.1 C) and 
its dihydro analogue towards a number of susceptible human tumor cell lines 




authors found that calythropsin had a weak effect on mitosis and presumably 
on tubulin polymerization as well. Furthermore, the cytotoxicities of 
hydroxychalcones have been found to be due in part to their abilities to 
uncouple mitochondrial membrane potential, such that substitution of fewer 
hydroxyl groups on both rings of the chalcones lead to greater effectiveness 
(Sabzevari et al., 2004). On the other hand, a number of methoxylated 
chalcones have been reported to possess antimitotic activity against HeLa 
human cervical cancer cells. A clear preference for the methoxy groups to be 
located on ring A but not ring B, as well as at α-position rather than β-position 
(structure refer to Table 1.1) for antimitotic activity has been reported 

















   
          C. Calythropsin 
 
Figure 1.1 Chemical structures of naturally occurring chalcones 
possessing cytotoxic effects. 
 
Chalcones have also been reported to possess chemopreventive properties. For 
instance, Licochalcone A (Figure 1.2 A), a naturally occurring chalcone found 
in Chinese liquorice displays inhibitory effect on tumor promotion (Shibata et 
al., 1991). There are also studies reporting that prenylated chalcones possess 
distinct chemopreventive profiles that are not observed with non-prenylated 
chalcones. The chemopreventive properties include anti-inflammatory, 
antioxidant, anti-invasive and anti-metastatic activities (Miranda et al., 2000; 
Stevens et al., 2003). The inflorescences of the female hop plant (Humulus 
lupulus) used in beer brewing industry contain a rich source of prenylated 
chalcones. These chalcones will be introduced later in Chapter 2 Section 2.1.  
Broussochalcone A (BCA) (Figure 1.2 B), isolated from Broussonetia 
papyyrifera Vent, has been demonstrated to possess antioxidant and 
anti-inflammatory activities (Cheng et al., 2001). Curcumin (Figure 1.2 C) is 
another chalcone with antioxidant and anti-metastatic effects (Aggarwal et al., 




(2001), chalcone Narigenin (Figure 1.2 D) isolated from Helichrysum 
maracandicum has been found to possess antioxidant activity. Narigenin also 
suppresses the expression of p38 mitogen activated protein kinase, which has 
been considered to contribute in part to the anti-cancer mechanism (Anto et al., 
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Figure 1.2 Chemical structures of naturally occurring chalcones 
possessing chemopreventive properties. 
 
1.1.2 Synthesized chalcones 
The wealth of pharmacological activities possessed by naturally occurring 
chalcones had aroused much interest among the scientific community to 
pursue synthetic chalcone analogs that have potential therapeutic applications 
in various disease states. 
 
Several groups have reported that the presence of hydroxy and methoxy 
substituents are favorable features for synthesized chalcones possessing 
various biological activities (De Vincenzo et al., 2000; Edwards et al., 1990; 
Monostory et al., 2003; Nam et al., 2003). Several 2,5-dihydroxychalcones 
have also been reported of exhibiting cytotoxicities against numerous human 
tumor cell lines (for example HCT 116 human colon cancer cells, A31 human 
epidermoid carcinoma cells), as well as non-tumor endothelial cell line 
[human umbilical venous endothelial cells, (HUVEC)]. Effects of chalcones 




property (Nam et al., 2003). The structure of 2,5-dihydroxy-2’-chlorochalcone, 
the most effective analog found in the study, is presented in Figure 1.3 A. 
Chalcones are also known to possess inducing or inhibitory activities on 
metabolic enzymes. A group of 4-hydroxylated chalcones have been reported 
to inhibit estrogen biosynthesis by inhibiting 17β-hydroxysteroid 
dehydrogenase (17β-HSD) and aromatase respectively (Le Bail et al., 2001). 
Cytochrome P450 enzymes regulate carcinogenesis by activating numerous 
procarcinogens into active forms, which in turn interact with cellular 
nucleophiles, nucleic acids and amino acids. 2’-methoxychalcone has been 
reported to be a good inhibitor of CYP1A-dependent metabolism of 
ethoxyresorufin (Monostory et al., 2003). The induction of phase II enzymes 
like GST and NQO1 is widely ascribed as an effective chemoprotective 
mechanism, and has been used experimentally as a marker to assess the 
chemopreventive abilities of compounds. Hydroxylated chalcones have been 
reported to be effective quinone reductase inducers (Dinkova-Kostova et al., 
1998). 1,3-Bis-(4-hydroxyphenyl)-propen-1-one (DHBA) (Figure 1.3 B) was 
found to inhibit the proliferation of MCF-7 human breast cancer cells by 
binding to nuclear type II site competitively with its endogenous ligand 
methyl-p-hydroxyphenyllactate (MeHPLA), which regulates normal and 
malignant cell growth and proliferation (Markaverich et al., 1990). In another 
study, among a series of chalcones bearing hydroxy and methoxy substituents 




possessing good antioxidant and anti-proliferative activities (Dinkova-Kostova 
et al., 2001a). 2-hydroxychalcone, for example, was identified to possess more 
superior antioxidant properties than unsubstituted chalcone, specifically, it has 
also been reported to possess antioxidant at low concentrations (0.01-1 μM), 
whereas at higher concentrations (10, 50 μM), it exerts anti-proliferative 
effects (Calliste et al., 2001). Furthermore, Ko et al. had reported that the 
2,5-dihydroxychalcone (Figure 1.3 C) brought about inhibition of NO 
production in LPS-activated macrophages (Ko et al., 2003). Another study has 
found that among a series of 
3,4,5-trimethoxychalcones,1-(3,4,5-trimethoxy-phenyl)-3-(3’-methoxy-phenyl
)-propen-1-ones (Figure 1.3 D) is the most potent analog inhibiting NO 
production (Rao et al., 2009). These studies therefore suggest that synthetic 
chalcones bearing hydroxy or methoxy substituents possess potential 
anti-inflammatory effects.  
 
Several chalcones have demonstrated anticancer activities. For instance, 
1-(2,5-dimethoxy-phenyl)-3-(4’-dimethylamino-phenyl)-2-methyl-propen-1-o
nes (Figure 1.3 E) has been reported of possessing anti-mitotic property 
(Edwards et al., 1988). A series of dihydrochalcones (Figure 1.3 F, G, H) has 
been reported to induce apoptosis in prostate cancer cells by augmenting 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (Szliszka et 




chalcones and found that 3,5-bis-(4-boronic 
acid-benzylidene)-1-methyl-piperidin-4-ones (Figure 1.3 I) exhibited potent 
anticancer activity through accumulation of p53 and p21 (Achanta et al., 2006). 
Another chalcone Ch55 (Figure 1.3 J) has been reported to suppress the c-myc 
oncogenes (Hashimoto et al., 1987). 
 
Chalcones have also been reported to possess anti-infectious activities. 
Dihydrochalcones asebogenin (Figure 1.3 K) has shown inhibitory effects 
against S.aureus and methicillin-resistant S. aureus (MRSA) (Joshi et al., 
2001). Another group of synthetic chalcones 
1-phenyl-3-(2’-hydroxy-3’-methoxy-phenyl)-propen-1-ones (Figure 1.3 L) 
have demonstrated potent effects against purified HIV-1 integrase in the 
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Figure 1.3 Chemical Structures of synthesized chalcones. 
 
1.2 Breast cancer overview 
1.2.1 Breast cancer progression and types 
Breast cancer is a malignant tumor that starts in the cells of the breast. It 
occurs mostly in women, but men also have likelihood of contacting breast 
cancer. Breast cancer is one of the leading lethal cancers; in female community, 




bronchus origin (Siegel et al., 2012). Such high mortality rate is mainly caused 
by the highly invasive nature of the tumor cells.  
 
There are many types of breast cancer. Sometimes a breast tumor can be a mix 
of these types or a mixture of invasive and in situ cancer. Ductal carcinoma in 
situ (DCIS) and lobular carcinoma in situ (LCIS) are non-invasive types of 
cancers with origins in the ducts and milk glands respectively. Invasive (or 
infiltrating) ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are 
invasive cancer types, with IDC being the most common type of breast cancer. 
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer 
but consists only 1% to 3% of all cases breast cancer. According to the 
receptor status, breast cancer can also be classified as estrogen receptor 
positive/negative (ER+/-) cancer, human epidermal growth factor receptor 2 
positive/negative (Her2 +/-) cancer, progesterone receptor positive/negative 
(PR+/-) cancer and triple-negative breast cancer. Triple-negative breast cancer 
refers to any breast cancer that does not express the gene for ER, Her2 and PR.  
 
Breast cancer progression begins with the normal breast terminal ductal 
lobular unit (TDLU), which contains lobules and ducts that consist of a 
bi-layered epithelium of luminal and myoepithelial cells. Induced by 
carcinogenic stimuli, atypical ductal hyperplasia (ADH) is formed as a 




lobule. ADH is thought to be the precursor of ductal carcinoma in situ (DCIS), 
which is a non-invasive lesion that contains abnormal cells. With each stage, 
the risk of developing malignant or invasive breast cancer (IBC) increases. 
DCIS may give rise to IBC, but it is unclear how to predict which lesions will 
progress. Once cells have invaded, the risk for developing metastasis 
significantly increases. The lymph nodes, lung, liver and bone are the primary 
sites of metastasis of breast cancer metastasis (Vargo-Gogola and Rosen, 
2007).  
1.2.2 Breast cancer treatments 
Treatment options for breast cancer may include surgery, radiation, 
chemotherapy, hormone or biological therapies. Adriamycin and 
cyclophosphamide combined (AC) or cyclophosphamide, methotrexate and 
fluorouracil combined (CMF) are often adopted in breast cancer chemotherapy 
(Oladipo et al., 2012). Other types of chemotherapies include the use of 
tamoxifen,  an antagonist of the estrogen receptor that is usually over 
activated in breast cancer (Weniger et al., 1982). Trastuzumab, a monoclonal 
antibody that interferes selectively with human epidermal growth factor 
receptor (HER)-2, is also used in treatment of breast cancers that are tested 
Her-2 positive (Ross and Fletcher, 1998).  
 
A number of chalcones are currently undergoing experimental testing for their 





displays potent anti-proliferative activity against MDA-MB-231 (poorly 
differentiated, p53-, pRB-, ER- and highly invasive) and MDA-MB-468 
(intermediately differentiated, PTEN-, ER- and moderately invasive) human 
breast carcinoma cells while having little toxicity on non-cancerous cells 
(Solomon and Lee, 2012). Chalcone-linked imidazolones are also reported to 
exhibit anti-cancer activity in breast cancer (Kamal et al., 2010). 
2,4-dimethoxy and 2,4-dihydroxy chalcones are found to significantly reverse 
breast cancer resistance protein (BCRP) activity, which suggests their potential 
as BCRP inhibitors (Han et al., 2008; Liu et al., 2008). Butein 
(3,4,2’,4’-tetrahydroxychalcone) isolated from the Rhus verniciflua Stokes 
stem is also found to inhibit the growth of micrometastases of breast cancer 
(Samoszuk et al., 2005).      
1.3 Tumor invasion and Matrix metalloproteinases (MMPs) 
Hanahan and Weinberg have proposed that there are eight hallmarks of cancer, 
including sustained proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, 
activating invasion and metastasis, reprogramming of energy metabolism and 
evading immune destruction (Hanahan and Weinberg, 2011). Among them, 
tumor invasion and metastasis has been responsible for 90% of cancer deaths 





The process of tumor invasion initiates from the induction and mediation by 
bone marrow-derived cells to change the local microenvironment suitable for 
secondary tumor at the target sites before the arrival of tumor cells by 
eipthelial-mesenchymal transition (EMT). Tumor cells detach from primary 
tumor along with proteolytic degradation of the extracellular matrix (ECM), 
then migrate and intravasate into blood or lymph vessels and get transported 
away to extravasate at distant sites where they grow into new micrometastases 
and form new secondary tumors (Geiger and Peeper, 2009). In the context of 
our study, the focus is mainly on tumor invasion. EMT has been regarded as 
an important process through which cells acquire the abilities to migrate, 
invade and to resist apoptosis (Kim et al., 2009). The epithelial tissues 
represent the origins of most solid tumors. During EMT, the epithelial cells 
acquire characters of mesenchymal cells, thereby acquiring invasive abilities 
to enhance cell migration (Thiery and Sleeman, 2006). Upon stimulation in the 
cells, E-cadherin, which helps to promote and maintain cell adhesion to ECM 
is switched to N-cadherin, which is a type of protein found in migrating 
neurons and mesenchymal cells; N-cadherin is usually up-regulated in many 
invasive carcinoma cells (Cavallaro and Christofori, 2004). The key signaling 
pathways inducing EMT include wnt, notch, hedgehog and NF-κB pathways 
(Huber et al., 2004; Massagué, 2008). Migration of tumor cells has also been 




mediators such as cadherins, some cell-cell adhesion proteins, integrins, CD44 
and immunoglobulin-domain cell adhesion molecules (IgCAMs) may be 
involved in the process (Friedl and Wolf, 2003; Guo and Giancotti, 2004; 
Ponta et al., 2003; Weber, 2008).   
 
The matrix metalloproteinases (MMPs) are a family of zinc-dependent 
enzymes contributing to the degradation of ECM (Stamenkovic, 2000; 
Westermarck and Kahari, 1999). More than 20 types of MMPs have already 
been discovered to date (Cavallaro and Christofori, 2004). MMP-1 
(Collagenase-1), MMP-8 (Collagenase-2) and MMP-13 (Collagenase-3) are 
mainly responsible for the degradation of native fibrillar collagens (collagen I, 
II, III, VII), with the products further degraded by MMP-2 and MMP-9 
(Gelatinase A & B) (Stamenkovic, 2000). MMP-9 can digest collagen IV in 
ECM and is believed to play the crucial role in tumor invasion (Brinckerhoff 
and Matrisian, 2002). Furthermore, several studies have shown that MMP-9 is 
overexpressed in human breast cancer cells and highly related to tumor 
migration, invasion and metastasis (Bourguignon et al., 1998; Kondapaka et 
al., 1997; Stuelten et al., 2005; Yao et al., 2001). In addition, several inhibitors 
against MMP-9 have been reported to inhibit tumor invasion (Bellosta et al., 
1998; London et al., 2003; Rao et al., 2005; Sartor et al., 2002), while MMP-2 
is believed to be constitutively expressed and insensitive to drug treatment 




MMP family and is able to degrade type IV collagen (Nagase and Woessner, 
1999).    
 
Western blot analyses from previous studies have shown that there are two 
bands, 85 kDa and 92 kDa, corresponding to two different forms of MMP-9. 
According to the report by Toth et al. (1997) using MCF10A (non-tumorigenic) 
breast epithelial cells, the upper bands (92 kDa) represented the mature form, 
while the lower bands (85 kDa) corresponded to the glycosylated form. The 85 
kDa glycosylated form is first formed and gradually converted to the mature 
92 kDa form (Toth et al., 1997). Controversially, in the report of the same 
research group in 2003, the 92 kDa MMP-9 had been recognized as 
pro-MMP-9, and the 85 kDa as the active form (Toth et al., 2003). Many other 
recent reports using breast carcinoma cell lines have all regarded 92 kDa 
MMP-9 as pro-MMP-9, while 85 kDa as the active form (Bellosta et al., 1998; 
Bourguignon et al., 1998; Kondapaka et al., 1997; Lin et al., 2008; Ling et al., 
2010; Okada et al., 1992; Stuelten et al., 2005).   
 
The pro-MMP-9 (92kDa) is known to be intracellularly synthesized, then 
secreted and activated in the extracellular space. However, interestingly, it 
remains unclear why the active form of MMP-9 is undetectable as only bands 
representing pro-MMP-9 have appeared in western blots (Toth et al., 2003). 




from various protease families including other MMPs, tissue inhibitors of 
metalloproteinase (TIMPs), membrane type-MMPs (MT-MMPs), or serine 
protease urokinase-type plasminogen activator (uPA) (Coussens et al., 1999; 
Han et al., 2002; Menashi et al., 1994; Okada et al., 1992; Sorsa et al., 1997) 
 
uPA can activate serine protease plasminogen to serine plasmin by attaching to 
its receptor urokinase-type plasminogen activator receptor (uPAR) (Chandler 
et al., 1995). The serine plasmin then activates the precursor forms of MMPs. 
It has been reported that uPA also activates pro-MMPs (Rao et al., 2005). 
TIMPs are the endogenous inhibitors of MMPs and there are to date four types. 
TIMP-1 is usually involved in the inhibition of MMP-9 (Clark et al., 2008), 
while TIMP-2 in the suppression of MMP-2 (Toth et al., 2000).  
1.4 Other small molecule compounds as anti-invasive agents on breast 
cancer cells 
There are many compounds have been reported to possess anti-invasive 
properties in breast cancer cells, such as parthenolide, 
3-isopropyl-2-methyl-4-methyleneisoxazolidin-5-one (MZ-6) (Wyrębska et al., 
2012) and 3β-hydroxylup-20(29)-ene-27,28-dioic acid dimethyl ester from 
plumbago zeylanica (Sathya et al., 2010) Several prenylated chalcones (Figure 
1.4 A, B, C) displayed anti-invasive properties against human mammary 




Parmar et al., 2003). Parmar et al (Parmar et al., 2003) had synthesized and 
screened a large series of chalcones on anti-invasive properties against 
MCF7/6
1
 breast carcinoma cells. The results showed that the following 
compound (Figure 1.4 D) inhibited invasion at 1 μM. Curcumin (Figure 1.2 C) 
and green tea polyphenols have also been reported as potent anti-invasive 





















                                                 
1 MCF-7/6 is an estrogen receptor-positive invasive human breast cancer cell line with a 



















Figure 1.4 Prenylated chalcones showed anti-invasive effect on breast 
carcinoma cells. 
 
1.5 Objectives  
Chalcones have long been explored for the treatment of various diseases 
(Katsori and Hadjipavlou-Litina, 2011). The multifunctional properties of 
chalcones make them promising to be used as anti-cancer agents. Although 
numerous chalcones have been discovered for their anti-proliferative effects 
on breast cancer cells, few studies are focused on exploring their anti-invasive 
effects in breast cancer. In this study, we were interested to investigate the 




several chalcones bearing hydroxy and methoxy substituents have been found 
to possess potent anti-cancer properties, a series of chalcone analogs 
substituted with hydroxy, fluoro and/or methoxy at the phenyl rings of the 
chalcone structure was synthesized and evaluated for potential anti-invasive 
activities in breast cancer cells. The structures of the synthesized chalcones for 
evaluation are presented in Table 1. Through the screening assays, we aimed to 
identify chalcones with structural features that would possess the most potent 
anti-invasive effects. To these lead chalcone analogs, we further aimed to 




Chapter 2: Evaluation of a series of chalcone analogs for potential 
anti-invasive effect on human-derived breast MDA-MB-231 and MCF-7 
carcinoma cells  
Summary 
In this chapter, cell viability assays were conducted on ten chalcone analogs to 
evaluate their cytotoxicity profiles. Non-cytotoxic concentrations of 5 and 10 
μM were selected for subsequent experiments to evaluate chalcones’ 
anti-invasive potential. The effects of these chalcones on MMP-9 proteolytic 
activity and expression levels in MDA-MB-231 and MCF-7 human breast 
carcinoma cells were studied. Based on the results obtained, four most potent 
chalcones were selected for further mechanistic investigation.  
2.1 Introduction 
Chalcones (1,3-diphenyl-2-propen-1-ones) are precursors in flavonoid 
biosynthesis in plants. Chalcones have been reported of possessing a variety of 
biological effects such as anti-inflammatory, anti-cancer, antioxidant and 
anti-infectious effects. Numerous chalcones present anticancer activities 
towards various cancer cell lines, including those derived from the prostate, 






Naturally-occurring chalcones are found to possess anti-invasive properties 
including xanthohumol and isoliquiritigenin. Xanthohumol is a prenylated 
chalcone discovered in hops (Humulus lupulus L.) and beer. Previous studies 





 cells (Vanhoecke et al., 2005). A recent study has 
also revealed that xanthohumol is an AKT/NF-κB inhibitor, which might be 
related to its anti-invasive property (Benelli et al., 2012).   
 
Isoliquiritigenin (ISL, 4,2’,4’-trihydroxychalcone) is another chalcone that has 
been reported of having anti-invasive property. This chalcone can be found in 
licorice, shallot and bean sprouts. A study by Kwon et al. had reported that the 
anti-invasive effect of ISL against human prostate DU145 cancer cells was at 
least in part mediated through JNK/AP-1 signaling pathway inhibition (Kwon 
et al., 2009). In addition, the anti-invasive and anti-metastatic effects of ISL 
have also been reported in human cervical Hela (Hsu et al., 2009) and breast 
















                                                 
2
 MCF-7/AZ is a human breast adenocarcinoma cell line that is not invasive in vitro 












B. Xanthohumol                       C. Isoliquiritigenin 
 
Figure 2.1 Chemical structures of chalcone, xanthohumol and 
isoliquiritigenin. 
 
Chalcones have constantly attracted the attention of researchers interested in 
anti-invasive and anti-metastatic drug discovery. In this project, a series of 
chalcone analogs were screened for possible anti-invasive property against 
breast carcinoma cells. The chalcones investigated bear hydroxyl and methoxy 
substituents at the 2- and/or 2’-position (Table 1). In addition, 5- and/or 
5’-fluoro substituents are present in a number of analogs CC4, CC5 and CC6. 
Interestingly, chalcone 1 (CC1), also known as 2’-hydroxychalcone, has been 
reported of possessing antioxidant activity (Go et al., 2005). However, none of 
the nine analogs have been studied for their anti-invasive effects in breast 
cancer. Since ISL is structurally similar to the chalcone analogs investigated, 
and also has been reported to possess anti-invasive effect in breast cancer, it 
was selected as the positive control in our experimental studies.  
 




by the metastatic spread of tumor cells. The initial step of tumor metastasis is 
tumor cell invasion, while the initial tumor cell invasion step involves 
cleavage of cell adhesion molecules, proteolytic degradation of the ECM, and 
cell migration (Ellerbroek and Stack, 1999; Westermarck and Kahari, 1999). 
MMPs are a family of structurally related zinc-dependent secreted and 
membrane-type proteases. They are main contributors to the degradation of 
ECM. Among over 20 discovered human MMPs (Murphy and Nagase, 2008), 
MMP-9 (gelatinase B) is believed to be the most important enzyme in tumor 
invasion due to its ability to digest the major component of ECM-type IV 
collagen (Nelson et al., 2000). MMP-9 is highly expressed in various 
malignant tumors including breast cancer (Chung et al., 2002; Nelson et al., 
2000). Therefore, in this study, the chalcones were screened in two 
PMA-induced breast carcinoma cell lines (MDA-MB-231 and MCF-7 cells) 
for their effects on gelatinolytic activity and levels of MMP-9. The most 
potent chalcones were identified to be studied in subsequent experiments as 
discussed in Chapters 3 and 4. 
2.2 Materials and methods 
2.2.1 Materials 
2.2.1.1 Reagents 
Chalcone analogs were synthesized by Dr Yang Hong and Miss Tu Ngoc ly 




gelatin from porcine skin (Type A) and DMSO were purchased from Sigma 
(St. Louis, MO). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was obtained from Duchefa Biochemie B.V. (A Hofmanweg, 
Netherlands). All chalcones analogs, ISL and PMA were dissolved in DMSO 
and stored at -20 ℃ as DMSO stocks. 
 
2.2.1.2 Antibodies 
Mouse monoclonal anti-MMP-9 and mouse monoclonal anti-β-actin 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Secondary antibody horseradish peroxidase (HRP)-conjugated goat 
anti-mouse IgG was from Thermo Scientific (Waltham, MA).  
 
2.2.2 Methods  
2.2.2.1 Cell Culture  
Human-derived MDA-MB-231 and MCF-7 carcinoma cells were obtained 
from American Type Culture Collection (Rockville, MD) and cultured in 
RPMI 1640 medium (GIBCO) supplemented with 10% fetal bovine serum 
(Hyclone Laboratories, Logan, UT), 100 U/ml penicillin G and 1 μg/ml 





2.2.2.2 Cell Viability Assay 
The effects of chalcone analogs on viabilities of MDA-MB-231 and MCF-7 
cells were determined using MTT assay. MTT is a yellow tetrazolium dye, 
which can be reduced by mitochondrial enzyme succinate-dehydrogenases in 
viable cells into insoluble blue formazan (Denizot and Lang, 1986; Mosmann, 
1983). The formazan crystals can be solubilized in DMSO, isopropanol, 
ethanol or other organic solvents (Carmichael et al., 1987; Plumb et al., 1989). 
The absorbance of the dissolved formazan is directly proportional to the 
number of living cells, which therefore allows the measurement of cell 
viability. 
 
The cells were seeded in 96-well plates at the density of 2 × 10
4
 cells 
suspended in 180 μl culture medium per well for both MDA-MB-231 and 
MCF-7 cells. The MDA-MB-231 and MCF-7 cells were allowed to attach and 
grow for 72 h and 48 h respectively till reaching 90-100% confluency, and 
then treated with drugs. The experimental drug solutions in culture medium 
were freshly diluted from the DMSO stock solutions before treatment and 
aliquots were dispensed into each well to achieve the adjusted final 
concentrations. After drug treatment for 24 h, 50 μl of MTT (2 mg/ml in PBS, 
filter-sterilized and stored in 4 ℃) was added to each well and the plates were 
incubated at 37 ℃ for 4 h. The formed formazan crystals in each well were 




at 550 nm using VersaMax ELISA microplate reader (Molecular Devices, LLC, 
Sunnyvale, CA). The effects were expressed as relative percentage cell 
viability over that of untreated cells. Viability of untreated cells was set as 
100%.  
 
2.2.2.3 Preparation of conditioned medium and whole cell lysates 
MDA-MB-231 or MCF-7 cells were plated in 6-well plates using RPMI 1640 
medium with 10% FBS and incubated until reaching 90% confluency. The 
cells were next incubated in serum-free medium for 12 to 16 h, after which 
chalcone analogs or ISL were added. After 1 h, cells were treated with PMA 
(80 nM) for 20 h. Conditioned medium was then collected and centrifuged at 
1.3 × 104 rpm for 10 min at 4 ℃ to remove cells and debris. The cell-free 
supernatants were used for gelatin zymography and western blotting.  
 
Upon removal of medium, the cells were gently washed with ice cold PBS, 
after which cells were lysed in Triton X-100 lysis buffer [25 mM Tris (pH 7.5), 
2.5 mM EDTA, 2.5 mM EGTA, sodium fluoride 20 mM, 1 mM sodium 
orthovanadate, 100 mM NaCl, 20 mM sodium beta-glycerophosphate, 10 mM 
sodium pyrophosphate, 0.5% Triton X-100] containing freshly added protease 
inhibitor cocktail stock solution (volume ratio 25:1) [Roche complete, 
EDTA-free protease inhibitor cocktail tablets, two pills were dissolved in 4 ml 




The collected whole cell lysates were centrifuged at 1.3 × 104 rpm for 10 
min at 4 ℃ to remove cell debris. Protein concentration of each sample was 
determined using Bradford protein assay (Bio-Rad Laboratories).  
 
2.2.2.4 Gelatin Zymography 
Gelatin zymography was performed to test the effects of chalcones on MMP-9 
gelatinolytic activities according to published protocols with slight 
modifications (Templeton et al., 1990). Bradford protein assay (Bio-Rad 
Laboratories) was used to determine levels of proteins in each sample. Upon 
determination of protein content, volumes of samples containing equal 
amounts of protein were mixed with 4X Laemmli buffer (volume ratio 3:1) 
[250 mM Tris (pH 6.8), 6% w/v SDS, 40% sucrose, 0.04% (w/v) bromophenol 
blue] without adding β- mercaptoethanol and kept at room temperature for 10 
min before being subjected to electrophoresis on a 12% SDS-PAGE gel 
containing 0.1% (w/v) gelatin. Following electrophoresis, the gels were 
washed twice in 2.5% Triton X-100 for 30 min for renaturation before 
equilibration for 30 min in developing buffer [50 mM Tris-HCl (pH 7.5), 10 
mM CaCl2, 0.2 M NaCl and 1 mM ZnCl2]. The gels were then incubated in 
fresh developing buffer at 37 ℃ for 72 h. The gels were stained with 
Coomassie blue stain [0.5% Coomassie blue R-250, 45% methanol, 10% 
acetic acid (v/v)] for 4 h, followed by destaining using destaining buffer [45% 




gelatinolytic activity of MMP9 was visualized as clear bands against a dark 
blue background of the gel. 
 
2.2.2.5 Western Blot Analysis   
Equal amounts of protein in whole cell lysates (30 μg) or conditioned medium 
(1 μg) were separated by electrophoresis on a SDS-PAGE gel. 12% resolving 
gel [formula for two gels: 5 ml 4X resolving gel buffer, 9 ml distilled water, 6 
ml 40% acrylamide, 120 μl 10% ammonium persulfate, 16 μl TEMED. 4X 
resolving buffer: 1.5 M Tris, 0.4% (w/v) SDS, adjust pH to 8.8 with HCl, up to 
100ml with distilled water] and 4% stacking gel [formula for two gels: 2.5 ml 
4X stacking gel buffer, 6.5 ml distilled water, 1 ml 40% acrylamide, 60 μl 10% 
ammonium persulfate, 8 μl TEMED. 4X stacking gel buffer: 0.5 M Tris, 0.4% 
(w/v) SDS, adjust pH to 6.8 with HCl, up to 100ml with distilled water] were 
casted. Samples of lysates containing equal amounts of proteins were mixed 
with 4X Laemmli buffer containing 15% (v/v) β-mercaptoethanol (volume 
ratio 3:1) and boiled at 100 ℃ for 10 min. The samples were then loaded into 
the wells in the SDS-PAGE gel and separated under constant voltage of 110V 
using running buffer (25 mM Tris, 192 mM Glycine and 0.1% SDS).  
 
After separation, proteins were transferred onto nitrocellulose membranes 
under constant voltage of 25V at 4 ℃ overnight in transfer buffer [25 mM 




with 10% (w/v) non-fat milk in TBS-T (113 mM NaCl, 25 mM Tris-HCl with 
0.05% Tween 20) on a shaker at room temperature for 1 h, then probed with 
primary antibody for 2 h, followed by appropriate secondary antibody for 1.5 
h. Unbound primary and secondary antibodies were removed by washing with 
TBS-T for three times (a 5 min interval between each wash). The membranes 
were developed using enhanced chemiluminescence [SuperSignal West Femto 
(Pierce) or Western Lightning Plus (PerkinElmer)] and images were obtained 
on X-ray film (CL-Xposure
TM
 Film Clear Blue X-ray film, Thermo Scientific, 
Rockford, USA).   
 
2.2.2.6 Statistical analysis 
Data was expressed as mean ± SD of three independent experiments. 
Statistical significance between treatment and control groups was analyzed 
using Student’s t-test. Values of p＜ 0.05 were considered statistically 
significant.  
2.3 Results 
2.3.1 Effects of chalcones, ISL and PMA on cell viability of MDA-MB-231 
and MCF-7 cells  
The effects of chalcones, ISL and PMA on the viability of MDA-MB-231 and 
MCF-7 breast carcinoma cells were evaluated using MTT assay. As shown in 




significant (p<0.05) cytotoxicities were observed at certain concentrations, 
while PMA and ISL exhibited negligible cytotoxicities within the range of 
concentrations tested. Among the chalcone analogs, CC4 and CC6 displayed 
strongest cytotoxicities; significant reduction in cell viability was observed at 
10 μM. In comparison, the cytotoxic effects of other chalcones were relatively 
weak. Analogs CC1, CC2, CC3 and CC5 appeared to be cytotoxic starting 
from 20 μM, CC7 and CC8 from 30 μM, while CC and CC9 from 40 μM. 
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Figure 2.2 Effects of chalcones, ISL and PMA on viability of 
MDA-MB-231 cells. MDA-MB-231 cells were seeded in a 96-well plate at 
density of 2 × 10
4
 cells per well and exposed to chalcones, ISL and PMA for 
24 h. Relative cell viabilities in percentage were then calculated as stated in 
Section 2.2.2.2. Data presented as columns was obtained from three 
independent experiments. Standard deviations are illustrated as bars.  * p ＜ 
0.05, versus untreated group.   
 
To examine whether chalcones were selective in their antiproliferative effects 
against a specific cell line, MTT assays were also conducted on another breast 
carcinoma cell line. The dose-response curves for each chalcone analog, ISL 
and PMA were presented in Figure 2.3. Concomitant with the antiproliferative 
profiles obtained for MDA-MB-231 cells, CC4 and CC6 had registered the 
strongest cytotoxicity against MCF-7 cells, with a 5 μM concentration 
reducing viability to 88% and 89% respectively. CC, CC1, CC2, CC5 and CC7 
reduced cell viability around 85% at 20 μM. For the remaining analogs, 
significant cytotoxic effects appeared at doses higher than 20 μM. Again, the 
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Figure 2.3 Effects of chalcones, ISL and PMA on viability of MCF-7 cells. 
In a 96-well plate, MCF-7 cells were plated at cell density of 2 × 10
4
 cells per 
well and were exposed to chalcones, ISL and PMA for 24 h. Relative cell 



































































2.2.2.2. Data presented as columns was obtained from three independent 
experiments. Standard deviation displayed as bars. * p ＜  0.05, versus 
untreated group.    
 
Based on the MTT assay results obtained for both breast carcinoma cell lines, 
chalcones were found to be relatively non-cytotoxic at doses less than 10 μM. 
Drug concentrations of 5 and 10 μM were therefore selected for further 
experiments.  
 
2.3.2 Effect of chalcones on MMP-9 gelatinolytic activity and secretion in 
PMA-induced MDA-MB-231 and MCF-7 cells      
Chalcones were evaluated for their anti-invasive potential against 
MDA-MB-231 and MCF-7 cells. Both cell lines are known to possess invasive 
capacities. Given that MMP-9 is important in mediating the invasion process 
of cancer cells, to assess the anti-invasive potential of the chalcone analogs, 
they were evaluated for possible inhibitory effect on MMP-9 gelatinolytic 
activity and the levels of MMP-9 secreted into the extracellular milieu. 
MDA-MB-231 cells were pretreated with chalcones for 1 h, followed by 
addition of PMA (80 nM) for another 20 h. Conditioned medium were 
collected and subjected to gelatin zymography to analyze the gelatinolytic 
activities of MMP-9. PMA-stimulated MDA-MB-231 cells showed a marked 




corresponding to pro-MMP-9 (molecular weight of 92 kDa) (lane 2 in Figure 
2.4). In contrast, serum-starved MDA-MB-231 cells that were unstimulated 
with PMA shared negligible MMP-9 gelatinolytic activity, as depicted by lack 
of bands in lane 1 of both gel images in Figure 2.4 (lane 1 in both gel images 
were co-loaded with medium samples and prestained protein ladder). Several 
chalcones were observed to bring about a dose-dependent reduction in MMP-9 
gelatinolytic activity, among which CC7 demonstrated the strongest inhibitory 
effect that was more potent than naturally-occurring ISL (Figure 2.4). CC3, 
CC6 and CC9 at 10 μM appeared to display greater inhibition than ISL 10μM. 
Of note, CC, CC2 and CC8 were not found to cause decrease in MMP-9 




Figure 2.4 Effects of chalcones and ISL on PMA-induced gelatinolytic 
activity of MMP-9 in MDA-MB-231 cells. After pretreatment with chalcones 
for 1 h, MDA-MB-231 cells were challenged with PMA (80 nM) for 20 h. 
Conditioned medium was analyzed by gelatin zymography for MMP-9 
gelatinolytic activity as detailed in Section 2.2.2.4.   
 
We next investigated the effects of chalcones on the amount of MMP-9 




conditioned medium were analyzed by western blotting. In agreement with 
results obtained from gelatin zymography, CC7 produced the strongest 
inhibition among the analogs. The inhibition effect was also greater than that 
produced by ISL (Figure 2.5). CC3, CC6 and CC9 were observed to reduce 
MMP-9 levels to a similar extent as ISL. On the other hand, CC1 and CC4 
produced weaker reduction in MMP-9 levels than ISL, and CC, CC2 and CC8 
failed to decrease the levels of extracellular MMP-9. The effects of chalcones 
on the levels of secreted MMP-9 in PMA-stimulated MCF-7 cells were 
conducted by Miss Alana Lim Yuan Ghee [BSc(Pharm)(Hons) 2012, National 
University of Singapore] and results were presented in Appendix I. In both 
breast carcinoma cell lines, the chalcone analogs were found to produce 
similar trends of inhibitory effect on levels of extracellular MMP-9. Only one 
exception was observed: CC2 at 10 μM brought about reduction in MMP-9 
levels in MCF-7 cells, whereas in MDA-MB-231 cells, the analog at similar 




Figure 2.5 Effects of chalcones and ISL on levels of secreted MMP-9 in 
PMA-induced MDA-MB-231 cells. MDA-MB-231 cells were exposed to 
PMA for 20 h after 1 h incubation with chalcones at indicated concentrations. 




using MMP-9 antibody.  
 
2.3.3 Effects of chalcones on MMP-9 expression in PMA-induced 
MDA-MB-231 and MCF-7 cells  
As illustrated by results presented in Section 2.3.2, several chalcones brought 
about a decrease in proteolytic activity and levels of secreted MMP-9. To 
determine whether these analogs could also decrease the levels of intracellular     
MMP-9, lysates of MDA-MB-231 cells presented with chalcones, followed by 
PMA stimulation, were analyzed by western blotting for MMP-9 levels. 
Meanwhile, β-actin (42 kDa) was probed to verify equal loading of the amount 
of protein in each lysates sample. It should be pointed out that the two bands 
observed in the western blots presented in Figure 2.6 were both MMP-9. The 
upper bands (92 kDa) representing as pro-form, while the lower bands (85 
kDa) corresponded to the active form (Toth et al., 2003). As depicted in Figure 
2.6, consistent with gelatin zymography (Figure 2.5) and western blot (Figure 
2.5) results of collected conditioned medium, CC1, CC3, CC4, CC6, CC7 and 
CC9 suppressed cellular MMP-9 expression in a similar trend. Similarly, 
experiments performed with lysates of PMA-induced MCF-7 cells pretreated 
with chalcones also produced results demonstrating the same trend of 
suppression of MMP-9 levels as that observed in collected conditioned 







Figure 2.6 Effects of chalcones on MMP-9 expression level in 
PMA-induced MDA-MB-231 cells. MDA-MB-231 cells were incubated with 
chalcones for 1 h, followed by 20 h treatment with PMA. Whole cell lysates 
were collected and analyzed by western blotting. Upper and lower bands 
corresponded to pro-form and active form of MMP-9 respectively. β-actin was 
probed as a control for equal loading.   
 
2.4 Discussion 
In this chapter, to exclude the possibility that cell death could affect the results 
in further research, MTT assay had been carried out to screen the chalcone 
analogs for their effects on cell viability. PMA and positive control ISL were 
also evaluated in the MTT assay to rule possibilities of cytotoxicities. The 
stimulating PMA concentration of 80 nM was found to exert negligible 
cytotoxicity and 5 and 10 μM of ISL were found to be non-cytotoxic. Among 
the chalcone analogs, CC4 and CC6 were found to exert the strongest 
cytotoxicities. Other chalcones were generally non-cytotoxic below 20 μM. As 
a result, 5 and 10 μM were selected as the two non-cytotoxic concentrations 
for subsequent experiments involving MDA-MB-231 and MCF-7 breast 







Although CC4 and CC6 could decrease MMP-9 gelatinolytic activity and 
expression levels, it was not clear whether these activities were attributed to 
their cytotoxic effects, as a dose of 10 μM was found to produce significant 
reduction in cell viabilities. They were therefore excluded from further studies. 
Based on the results obtained with MDA-MB-231 and MCF-7 cells, CC, CC2 
and CC8 were not selected for further experiments due to their lack of 
suppressive activity on MMP-9 gelatinolytic activity and levels. CC1, CC3, 
CC7 and CC9 had been selected as the chalcones demonstrating potent 
suppressive effects on MMP-9 and were included for further studies as to be 
discussed in Chapter 3. Among the analogs, CC1 and CC7, as well as CC3 and 
CC9 bear substituents as the serine positions on Ring A and B; CC1 and CC3 
has 2’-hydroxy and 2,2’-dihydroxy substituents respectively, while CC7 and 
CC9 has 2-methoxy and 2,2’-dimethoxy substituents respectively. 
Interestingly, CC2 and CC8 bear hydroxyl and methoxy substituents at the 
2’-position respectively. However, there two compounds were found 
ineffective in decreasing MMP-9 levels. Taken together, the results had 
suggested that a hydroxyl or methoxy substituent placed at the 2-posistion in 
Ring A of a chalcone structure plays a more influential role in accounting for 




Chapter 3: Investigation of the effects of chalcones on cell migration and 
MMPs, uPA levels in PMA-induced breast carcinoma MDA-MB-231 cells    
Summary 
In this chapter, the anti-invasive effects of CC1, CC3, CC7 and CC9 on 
MDA-MB-231 cells were further examined. Wound-healing assay were 
carried out and MMP-9, MMP-2 and uPA expression and secretion levels were 
analyzed by western blot. Results obtained showed that CC7 and CC9 
exhibited strong suppressive effects on MMP-9 and uPA levels. Therefore, 
these two compounds were further studied for their effects on the 
transcriptional expressions of MMP-1, MMP-7, MMP-9 and MMP-13 genes 
using RT-PCR. It was found that both chalcones could decrease the mRNA 
levels of MMP-9, which might contribute to the reduction of MMP-9 
expression levels. Furthermore, MMP-7 mRNA levels were also suppressed 
by CC7 at 10 μM, suggesting that chalcones might affect the signaling 
pathways that regulate these MMPs.  
3.1 Introduction 
The initial process of cell invasion involves several steps such as degradation 
of ECM followed by cell migration. The wound-healing assay is a classic 




to study cell migration, matrix remodeling and other processes (Lampugnani, 
1999). Several studies have also adopted this method for the discovery of 
small molecules that affect cell migration (Adams et al., 2010; Kwon et al., 
2009; Weng et al., 2010). The critical step for tumor invasion and metastasis is 
the breakdown of basement membrane. This process requires activation of 
proteolytic enzymes such as MMPs (Liotta and Stetler-Stevenson, 1991; 
Parsons et al., 1997). Besides MMP-9, MMP-2 (gelatinase A) is also involved 
in the degradation of Type IV collagen in the ECM and has been associated 
with tumor invasion and metastasis (Baum et al., 2007; Brooks et al., 1996). 
MMP-2 is usually constitutively expressed and regulated by its inhibitors 
(Baker et al., 2002; Bernardo and Fridman, 2003; Clark et al., 2008; Gill and 
Parks, 2008). On the other hand, studies have also demonstrated that MMP-1, 
MMP-7 and MMP-13 may also be involved in the tumor invasion process 
through several ways, such as activation of pro-gelatinases (pro-MMP-2, 
pro-MMP-9) (Knäuper et al., 1997; Vincenti and Brinckerhoff, 2002; Wang et 
al., 2005) and interactions with cell adhesion molecules (for example: 
β-catenin/E-cadherin, integrins and cytokines) (Curran and Murray, 2000). 
Many inhibitors of these MMPs have provided evidence of their anti-invasive 
properties in different tumor types (Lin et al., 2008; Ling et al., 2010; London 
et al., 2003; Park et al., 2005; Rao et al., 2005; Shi et al., 2009). Given the 




cell invasion, chalcone analogs were examined for their ability to suppress 
MMP levels, which might render support for their anti-invasive potential. 
 
uPA is a serine protease that activates the serine protease plasminogen into 
plasmin, which in turn either directly degrades matrix proteins such as 
collagen IV or activates pro-MMP-9 and pro-MMP-2 (Danø et al., 1985; 
Schmitt et al., 1992; Sheela and Barrett, 1985). Furthermore, uPA also plays 
roles in cell adhesion and migration (Legrand et al., 2001; Ossowski and 
Aguirre-Ghiso, 2000). Over expression and secretion of uPA in advanced 
breast cancer has been reported by numerous studies (Costantini et al., 1996; 
Sliva et al., 2002b; Xing and Rabbani, 1996). Green Tea polyphenols have 
been reported to inhibit tumor invasion in breast cancer cells at least through 
down-regulation of uPA levels (Slivova et al., 2005). Blueberry 
phytochemicals are also reported of suppressing uPA expression in 
MDA-MB-231 cells, which therefore assist in inhibition of metastatic invasion 
of these breast cancer cells (Adams et al., 2010). Therefore inhibition of uPA 
levels has been proposed to be another target for novel anti-invasive and 
anti-metastatic drug discovery.   
 
As previous studies in Chapter 2 had demonstrated that CC7 was the most 




similar structure to that of CC7 (Table 1.1, Figure 2.2) with isosteric 
replacement of the 2-methoxy substituent with a 2-methylsulfanyl substituent, 
was synthesized by Miss Ng Hui Li [PhD candidate (Pharm) 2011, National 
University of Singapore]. HCL-15 had been included in our experiments, 






Figure 3.1 Chemical structure of HCL-15. 
3.2 Materials and methods 
3.2.1 Reagents and antibodies 
RNeasy
®
 Mini Kit was obtained from Qiagen (Hilden, Germany), 
RevertAid
TM
 First Strand cDNA Synthesis Kit #K1621 #K1622 was from 
Fermentas (Hanover, MD), mouse monoclonal anti-MMP-9, rabbit polyclonal 
anti-MMP-2, rabbit polyclonal anti-uPA, and mouse monoclonal anti-β-actin 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Mouse anti human MMP-7 antibody was obtained from Millipore (Temecula, 




anti-rabbit IgG were from Thermo Scientific (Waltham, MA). Chalcones, ISL, 
HCL-15 and PMA were reconstituted in DMSO as stocks and stored at -20 ℃.  
 
3.2.2 Methods 
3.2.2.1 Cell culture and treatment  
MDA-MB-231 cells were cultured as described in Chapter 2 Section 2.2.2.1. 
Upon reaching 90% confluency, cells were incubated in serum-free RPMI 
1640 medium for 12 to 16 h before being treated with the compounds and 
PMA (80 nM).  
 
3.2.2.2 Wound-healing assay 
MDA-MB-231 cells were plated in 6-well plates till reaching 90% confluency 
before being incubated in serum-free medium for 12 to 16 h. The monolayer 
of cells was scratched with a sterile 200 μl pipette tip, followed by gentle 
rinsing of the monolayer with serum-free medium to remove floating cells. At 
this zero time point, microscopic images were captured using the camera 
connected to the Nikon Eclipse Ti microscope (Nikon Instruments). The cells 
were then treated with chalcones and ISL for 1 h before being induced by 
PMA (80 nM) addition for another 20 h, after which the cells were washed 




3.2.2.3 Preparation of conditioned medium and whole cell lysates  
Conditioned medium and whole cell lysates preparation were as described in 
Chapter 2 Section 2.2.2.3.  
 
3.2.2.4 Western blot analysis 
Western blot analysis was carried out as described in Chapter 2 Section 
2.2.2.5.  
 
3.2.2.5 RNA extraction and reverse transcription - PCR (RT-PCR) 
MDA-MB-231 cells were seeded in 60 mm cell culture dishes till reaching 90% 
confluency. The cells were then maintained in serum-free medium for 12 to 16 
h, followed by treatment with chalcones and ISL for 1 h, and then incubated 
with PMA (80 nM) for another 5 h. Upon removal of conditioned medium, 
total RNA from each cell sample was extracted using an RNeasy
®
 Mini Kit 
(Qiagen, Hilden, Germany). According to the manufacturer’s protocol, cells 
were gently washed once with PBS and then scraped in 350 μl of RLT lysis 
buffer. After homogenization with a QIAshredder homogenizer, cell lysates 
were mixed thoroughly with 350 μl of 70% ethanol, and the mixture was then 
transferred into an RNeasy spin column and centrifuged for 2 min at 1.3 × 10
3
 
rpm to remove ethanol. The column was then washed once with 700 μl of 




respectively at 1.3 × 10
3
 rpm. Total RNA was eluted with 50 μl of RNase-free 
water. The concentration of RNA in each sample was determined using 
NanoDrop 1000 Spectrophotometer (Thermo Scientific).  
 
The total RNA from each sample was reverse-transcripted into single-stranded 
cDNA using RevertAid
TM
 First Strand cDNA Synthesis Kit #K1621 #K1622 
(Fermentas, Hanover, MD). The calculated volume of sample containing 4 μg 
of RNA was mixed with 1 μl of Oligo (dT)18 primer and made up to a final 
volume of 12 μl with nuclease-free water. The mixture was maintained in 65 ℃ 
for 5 min, and then mixed with 4 μl of 5X reaction buffer, 1 μl of RiboLockTM 
RNase Inhibitor (20 u/μl) and 2 μl of 10 mM dNTP Mix. The mixture was 
kept at 37 ℃ for 5 min. After addition of 1 μl of RevertAidTM M-MuLV 
Reverse Transcriptase (200 U/μl), the 20 μl mixture was incubated at 42 ℃ 
for 60 min, followed by 10 min heating at 70 ℃ to quench the reaction. The 
cDNA samples were then stored in -80 ℃ prior to use.  
 
Specific gene fragments were amplified in reaction solution (10 μl) containing 
1 μl of generated cDNA, 1 μl of deoxyribonucleotide triphosphate (2 mM), 
0.05 μl of Taq DNA Polymerase (5000 U/ml, New England Biolabs, Ipswich, 
MA) and 0.5 μl of each specific forward and reverse primers (5 nM) in 




15 s annealing at 58 ℃ for MMP-9 and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and 54 ℃ for other MMPs, 30 s extension at 70 ℃. 
The PCR was run for 31 cycles. The primer sequences used were as follow: 
MMP-9 (620 bp): forward,  5’-CGATGACGAGTTGTGGTCCCTGGGC-3’, 
reverse,  5’-AATGATCTAAGCCCAGCGCGTGGC-3’ (Zhang et al., 2006); 
GAPDH (496 bp): forward, 5’-CAAGGTCATCCATGACAACTTTG-3’, 
reverse, 5’-GTCCACCACCCTGTTGCTGTAG-3’[RevertAidTM First Strand 
cDNA Synthesis Kit #K1621 #K1622 (Fermentas, Hanover, MD)]; MMP-7 
(363 bp): forward, 5’-AGGAGGCGGGAGGCATGAGT-3’, reverse, 
5’-GCAGGGGGATCTCTTTGCCCC-3’;   MMP-1 (516 bp): forward, 
5’-TGAGGGGAACCCTCGCTGGG-3’, reverse, 
5’-GGGGTTTGTGGGCCGATGGG-3’; MMP-13 (663 bp): forward, 
5’-CCCTGCCCCTTCCCAGTGGT-3’, reverse, 
5’-TGAGTGCTCCAGGGTCCTTGG-3’ (Ling et al., 2010). The products of 
PCR were next subjected to electrophoresis on 1% agarose gels containing 
SYBR
®
 Safe (Vernier, Beaverton, OR) and images were captured under UV 
light in a Bio-Rad Gel Doc
TM
 XR+ System (Hercules, CA). 
 
3.2.2.6 Statistical analysis   






3.3.1 Effects of chalcones and ISL on cell migration in PMA-induced 
MDA-MB-231 cells 
The wound-healing assay was carried out to examine the effects of chalcones 
on cell migration. As shown in Figure 3.2, when light microscope images 
taken at T0h and T20h of DMSO-treated MDA-MB-231 cells (PMA-) were 
compared, the scratch gap had narrowed by the 20
th
 hour. The narrowing of 
the scratch gap in the absence of a stimulant was expected, given the intrinsic 
invasive nature of MDA-MB-231 cells. In contrast, for PMA-treated cells 
(PMA+), microscopic observations revealed a much obscured scratch gap 20 h 
after PMA stimulation. This had clearly indicated that PMA had successfully 
induced cell migration. Upon comparing drug treated groups with PMA+ 
group at T20h, all tested chalcone analogs, as well as ISL demonstrated 
inhibitory effects on cell migration as the scratch gaps, though narrowed, still 
remained clearly visible. CC1, CC7 and CC9 showed at both 5 and 10 μM 
suppressive effects displayed on cell migration and were as effective as ISL. 
Notably, among the chalcones; it was observed that CC3 displayed some 
cytotoxicity, as evident from the stressed morphology of the treated cells 
(Figure 3.2). As such, though cell migration was inhibited, we could not rule 










Figure 3.2 Inhibitory effects of chalcones and ISL on cell migration in 
PMA-induced MDA-MB-231 cells. Upon incubation in serum-free medium 
for 12 to 16 h, the monolayer of cells in 6-well plates was scratched and 
imaged at T0h. The cells were then treated with chalcones or ISL for 1 h before 




the cells were taken again at T20h. The detailed method was decribed in 
Section 3.2.2.2.    
 
3.3.2 Effects of chalcones and ISL on MMP-9, MMP-2, uPA secretion and 
expression in PMA-induced MDA-MB-231 cells  
Based on results obtained in Chapter 2, CC1, CC3, CC7 and CC9 had 
demonstrated impressive suppressive effects on MMP-9 secretion and 
expression in PMA-stimulated MDA-MB-231 and MCF-7 cells. They were 
therefore selected for further investigation. HCL-15, a chalcone analog 
structurally similar to CC7 with isosteric replacement of 2-methoxy to 
2-methylsulfanyl substituent, was evaluated alongside. MDA-MB-231 cells 
were pretreated with selected chalcone analogs for 1 h, followed by PMA 
stimulation for 20 h. Collected conditioned medium and whole cell lysates 
were analyzed by western blotting. As depicted in Figure 3.3, CC7 produced 
the strongest suppressive effects on MMP-9, followed by CC3, CC9, and lastly, 
CC1, while HCL-15 had no obvious effect. As such, HCL-15 was excluded 
from further studies. Of note, the results obtained for the four selected 
chalcone analogs were consistent with those obtained in earlier experiments as 







Figure 3.3 Effects of chalcones, HCL-15 and ISL on the secretion and 
expression of MMP-9 in PMA-induced MDA-MB-231 cells. The cells were 
pretreated with chalcones for 1 h before being challenged with PMA (80 nM) 
for another 20 h. Conditioned medium and whole cell lysates were analyzed 
by western blotting as described in Chapter 2 Section 2.2.2.5.  
 
MMP-2 expression levels in cell lysates were also examined by western 
blotting. The upper bands represented the pro-form of MMP-2 (72 kDa), and 
the lower bands were the enzymatically active form (62 kDa) (Shamamian et 
al., 2001). As shown in Figure 3.4, the expression level of active MMP-2 was 
higher than its proenzyme form in MDA-MB-231 cells. Although PMA (80 
nM) failed to induce active MMP-2 expression, it had caused a slight 
induction of its pro-form. Notably, all the tested chalcone analogs, including 







Figure 3.4 Effect of chalcones and ISL on MMP-2 expression in 
PMA-induced MDA-MB-231 cells. After pretreatment with the compounds 
for 1 h, the cells were challenged with PMA (80 nM) for 20 h. The whole cell 
lysates were then subjected to western blot analysis (refer to Section 2.2.2.5 in 
Chapter 2). 
 
uPA is known to activate the serine protease plasminogen into plasmin. 
Plasmin then directly activates pro-forms of MMPs (Sliva et al., 2002a). Over 
secretion and expression of uPA has been reported in many cancer types, 
including breast cancer (Markaverich et al., 1990; Rao et al., 2005; 
Schmalfeldt et al., 2001; Sliva et al., 2002a). We had probed the collected 
conditioned medium and lysates for levels of uPA. Results showed that 
stimulation with PMA (80 nM) had increased uPA secretion and expression 
(lane 2 in Figure 3.5). Among the chalcones, CC7 was again the most potent 
analog in bringing about great suppression of uPA secretion, whereas CC9 
only produced modest reduction in uPA secretion (Figure 3.5). CC3 at 10 μM 
also brought about significant reduction in uPA secretion. Interestingly, the 




differed from results obtained with conditioned medium; CC3 and CC7 did 
not decrease uPA levels while CC9 and ISL caused a significant decrease 
(Figure 3.5). As for CC1, no obvious suppressive effect on uPA secretion in 




Figure 3.5 Inhibitory effects of chalcones and ISL on uPA secretion and 
expression level in PMA-induced MDA-MB-231 cells. The cells were 
pretreated with drugs for 1 h, and then incubated with PMA (80 nM) for 20 h. 
Conditioned medium and lysates were then subjected to western blotting as 
described in Chapter 2 Section 2.2.2.5.  
 
3.3.3 Effects of CC7 and CC9 on transcriptional expression of certain 
MMPs in PMA-induced MDA-MB-231 cells 
Based on the results as presented in Figure 3.3 and 3.5, CC1 possessed the 
least anti-invasive potential among the four selected chalcones. As for CC3, 
though effective in causing reduction of the MMP-9 and uPA levels, we could 
not rule out that such effects could be due to certain degree of CC3’s 




cells to detach. Therefore, CC7 and CC9 had been selected for evaluation of 
their possible effects on the transcriptional expression of several MMPs.  
 
Besides MMP-9 and MMP-2, other MMPs such as MMP-7 (Matrilysin), 
MMP-1 (Collagenase-1) and MMP-13 (Collagenase-3) are also believed to 
play roles in the processes of cancer invasion and metastasis (Adams et al., 
2010; Heikkilä et al., 2002; Murray et al., 1998; Ueno et al., 1997; Yamashita 
et al., 1998; Yuan et al., 2005). In this research, transcriptional expression of 
MMP-9, MMP-7, MMP-1 and MMP-13 were examined in PMA-induced 
MDA-MB-231 cells using RT-PCR. As demonstrated in Figure 3.6, the mRNA 
levels of house-keeping gene GAPDH remained unaffected and were regarded 
as the loading control for each sample. A marked induction in MMP-9 mRNA 
level in the PMA-treated group was observed, while the induction in MMP-7 
seemed to be marginal (lane 2 in Figure 3.6). MMP-13 and MMP-1 failed to 
be induced by PMA. Treatment with CC7 and CC9 brought about a 
dose-dependent decrease in MMP-9 mRNA expression; suppressive effect of 
CC7 was stronger than that of CC9 at 10 μM. Furthermore, CC7 exert a slight 
suppressive effect on MMP-7 mRNA expression, but was ineffective in 
suppressing MMP-13 and MMP-1. CC9 did not produce suppressive effects 







Figure 3.6 Effects of CC7 and CC9 on transcriptional expression of 
MMP-9, MMP-7, MMP-13 and MMP-1 in PMA-induced MDA-MB-231 
cells. After pretreatment with CC7 and CC9 for 1 h, the cells were incubated 
with PMA (80 nM) for another 5 h. The transcriptional expressions of MMPs 
were detected by RT-PCR as detailed in Section 3.2.2.5.  
 
3.4 Discussion 
All the four chalcone analogs were found to inhibit local cell migration. 
However, though CC3 suppressed cell migration, obvious morphology 
alterations at 5 μM could be observed in the cells, treated cells looked 
morphologically stressed, which could be attributed to CC3’s cytotoxic effects. 
Based on the inhibitory effects on MMP-9 levels, CC7 was the most effective 
chalcone, while CC1 was the least. Interestingly, the structures of CC1 and 
CC7 share the same backbone with the only difference in the hydroxyl 




and CC9 also share the structure backbone with 2’-hydroxyl group in CC3 and 
2’-methoxy group in CC9. Although CC3 seemed to be more effective than 
CC9 in decreasing MMP-9 level at 10 μM, approximately 10% cell 
detachment has been discovered for CC3. While the results in MTT assay for 
CC3 (Figure 2.3 and Figure 2.4) did not demonstrate significant cytotoxicity, 
the detached cells might be due to the unhealthy conditions of the 
serum-starved cells rather than cell death. Nevertheless, this observation raised 
the possible postulation that methoxy substituents on 2 and/or 2’ position in 
the chalcone backbone might contribute towards low cytotoxicity and 
anti-invasive property. To provide support for the above hypothesis, HCL-15 
bearing 2-methylsulfanyl substituent was synthesized and included in our 
screening experiments. Concentrations of 5 and 10 μM, determined by MTT 
cell viability assays to be non-cytotoxic (data not shown) were used. However, 
this compound did not show inhibitory effects on MMP-9 level (Figure 3.3). 
Therefore it had been excluded for further exploration. The result had 
suggested that the methoxy substituent on 2-position could play a crucial role 
in the anti-invasive effects of chalcones. For further work to affirm this 
structure-activity relationship, many more chalcone analogs would be 
synthesized and screened for anti-invasive potential.    
 




found in the basement membrane of ECM (Brinckerhoff and Matrisian, 2002). 
Numerous studies have reported that MMP-2 expression is highly involved in 
tumor invasion in different tumor types (Brooks et al., 1996; Murphy and 
Nagase, 2008), including breast cancer (Baum et al., 2007; Duffy et al., 2000). 
Though PMA had been reported previously for use as a tumor invasive and 
metastatic promoter (Shimao et al., 1999), it failed to increase MMP-2 
expression level in this experiment. Similar results have been demonstrated in 
other published studies (Hanemaaijer et al., 1993; Lin et al., 2008). MMP-2’s 
lack of sensitivity for modulation is due to the lack of well-characterized 
regulatory elements in the gene’s promoter region (Mauviel, 1993). Detailed 
sequence analysis of the human MMP-2 promotor region in subsequent studies 
has revealed that a number of binding sites indeed exist, such as p53, 
cAMP-response element-binding protein (CREB), SP1, SP3 and AP-2 
(Overall and Lopez-Otin, 2002; Qin et al., 1999). However, unlike the 
promoter region of MMP-9 gene, the promoter region of MMP-2 gene does 
not contain binding sites for AP-1 and NF-κB, which are responsible to PMA 
stimulation. Therefore, the structural differences between the two genes might 
explain of the lack of response as displayed in Figure 3.4.  
 
uPA is also involved in the process of tumor invasion and metastasis in breast 




results obtained in Figure 3.3, CC7 displayed the best effect in decreasing the 
secretion of uPA at 5 μM, while CC9 appeared to be more potent than other 
chalcones in the reduction of uPA expression. However, the suppressive 
effects of CC3 and CC1 were rather weak. It was possible that the efficacies of 
CC7 and CC9 were due to the 2/2’-methoxy substituents on their structures as 
compared to CC1 and CC3. But it is remained unknown why CC7 appeared to 
be more potent in the reduction of uPA secretion, while CC9 was more potent 
in suppressing uPA expression. One possible explanation might be the 
additional 2’-methoxy group on CC9, which could have contributed to the 
differences in the suppression profile of uPA. In addition to the differences in 
the number and position of methoxy groups in these two compounds, the 
chemical spaces may contribute to the variable results. The chemical space can 
be defined as a region characterized by a wide range of “descriptors” of small 
molecular compounds including their molecular mass, lipophilicity and 
topological features. These features may affect the biological functions upon 
regulating the specific binding interactions between small molecule 
compounds and the three-dimensional biological molecules (Dobson, 2004; 
Lipinski and Hopkins, 2004). Petersen et al. had reported in 1988 that uPA 
was secreted as a single chain (sc) protein (sc uPA), which was the inactive 
form (pro-uPA) (Petersen et al., 1988). Generally, the secretion happens 




might follow the pathways that regulate its secretion (Larsson et al., 1984; 
Petersen et al., 1988). In summary, we postulated that CC7 might target these 
pathways, while CC9 could not, which therefore accounted for CC7’s efficacy 
in suppressing uPA secretion. Still, more research work needs to be performed 
to investigate this postulation.    
 
The down-regulation of MMP-9 levels by CC7 and CC9 could in some way be 
related to the suppression of MMP-9 mRNA levels in MDA-MB-231 cells 
(Figure 3.6). Besides being directly involved in mediating the process of 
tumor invasion (De Vicente et al., 2007; Heikkilä et al., 2002), MMP-7 and 
MMP-13 have also been reported to activate pro-MMP-9 (Fridman et al., 1995; 
Knäuper et al., 1997; Wang et al., 2005). Therefore, the reduction of MMP-7 
mRNA level by CC7 at 10 μM could lead to a further suppressive effect on   
pro-MMP-9 activation. The reason why PMA (80 nM) failed to induce the 
mRNA level of MMP-7 as effective as that of MMP-9, and not at all for 
MMP-13 might be due to the imperfect experimental conditions employed in 
our study. Optimization of experimental conditions would be required in our 
future work. Since the chalcones may be involved in regulating the 
transcriptional activity of the MMP genes, we deduced that chalcones might 
suppress transcriptional activity of MMPs through targeting the NF-κB and 




effects of chalcones on these two signaling pathways were carried out in 





Chapter 4: Investigation of the anti-invasive property of chalcones 
through NF-κB and MAPK/AP-1 signaling pathways in PMA-induced 
MDA-MB-231 breast carcinoma cells    
Summary 
In this chapter, the mechanisms of how chalcones down-regulated MMP-9 and 
exerted anti-invasive properties had been studied through NF-κB and 
MAPK/AP-1 signaling pathways in PMA-induced MDA-MB-231 cells. The 
inhibition of MMP-9 transcription may be due to chalcones’ suppressive 
effects on NF-κB signaling. Chalcones demonstrated inhibitory effects on 
phospho-IKKα/β, which thereby mediated the down-regulation of IκBα 
phosphorylation and degradation, and further resulted in the suppression of 
p65 phosphorylation and nucleus translocation, so that transcriptional 
expression of MMP-9 had been decreased. For MAPK signaling, chalcones 
showed no effects on p44/42 and p38 subgroups, but resulted in the 
diminution of SAPK/JNK cascades, which may cause the inhibitory effects in 
AP-1 signaling. All above, by mainly targeting at NF-κB and also affecting 
MAPK/AP-1 signaling, chalcones exhibited anti-invasive properties by 






Nuclear factor-κB (NF-κB), made up of p50 and p65 subunits, is normally 
located in the cytoplasm in an inactivated form associated with its inhibitor 
protein, inhibitor of kappaBα (IκBα). Upon application of an appropriate 
stimulus, such as inflammation, immunity or apoptosis, IκBα will be 
phosphorylated by phosphorylated IκB kinase complex (p-IKKα/β). The 
phosphorylated form of IκBα is ubiquitinylated and targeted for proteasomal 
degradation, which therefore allows the translocation of p50 and p65 subunits 
into the nucleus for binding to NF-κB binding sites on promoter regions of 
NF-κB target genes (Viatour et al., 2005).  
 
Activator protein 1 (AP-1) is involved in important cellular activities, such as 
proliferation, transformation, inflammation and apoptosis (Shaulian and Karin, 
2002). It is a heterodimeric protein composed of proteins from c-Fos, c-Jun, 
ATF and JDP family. The activation of AP-1 is induced by growth factors, 
cytokines, neurotransmitters and a variety of biological, physical and chemical 
stresses. These stimuli may in turn activate mitogen activated protein kinase 
(MAPK) signaling pathway, which may enhance AP-1 activity through the 
phosphorylation of distinct substrates (Chang and Karin, 2001). MAPK family 
contains extracellular signal regulated kinase (ERK) (p44/42), c-Jun 
N-terminal kinase (SAPK/JNK) and p38 subgroups. SAPK/JNK and p38 




pro-inflammatory cytokines and genotoxic stress. Upon activation, the 
SAPK/JNK translocates to the nucleus (Cavigelli et al., 1995), and activates 
c-Jun by binding and phosphorylation on Ser63 and Ser73. The activated c-Jun 
then enhances AP-1 transcriptional activity (Karin, 1995; Karin and Hawkins, 
1996).   
 
The activation of NF-κB and AP-1 has been reported in several breast cancer 
cell lines (Daschner et al., 1999; Nakshatri et al., 1997; Sovak et al., 1997). 
NF-κB can further interact with AP-1 to facilitate its transcription (Stein et al., 
1993). A NF-κB-binding site is located at -600 bp in the human MMP-9 
promoter (Mercurio and Manning, 1999). Though the MMP-13 gene does not 
contain NF-κB binding sites, several studies have reported that inhibition of 
NF-κB signaling can also decrease the expression level of MMP-13 (Burrage 
et al., 2006; Fan et al., 2006; Forsyth et al., 2006; Yan and Boyd, 2007). The 
mechanism involved is still unknown, but it is possible that the regulation is 
through NF-κB interaction with other transcription factors or through the 
non-canonical signaling of NF-κB. According to Yan and Boyd’s report, 
MMP-1, MMP-7, MMP-9 and MMP-13 belong to the same group based on 
the composition of cis-elements, which contain a TATA box of approximately 
-30 bp and an AP-1-binding site of approximately -70 bp. However, MMP-2 
has been included in another group without the TATA box and the transcription 




2007). Chakraborti et al. had previously reported that this group of 
SP-1-dependent MMPs were mainly constitutively expressed and modestly 
affected by growth factors or cytokines (Chakraborti et al., 2003). Besides, the 
uPA promoter also contains binding sites for transcription factors such as AP-1, 
NF-κB and PEA3, and participates in the regulation of uPA expression (E et al., 
1996; Nerlov et al., 1991).  
 
Since chalcones demonstrated anti-invasive properties through 
down-regulation of MMPs (MMP-9, MMP-7 and MMP-13) and other related 
upstream proteins such as uPA, we had investigated whether the mechanisms 
of their anti-invasive potential were mediated through NF-κB and MAPK 
signaling pathways in this chapter.  
4.2 Materials and Methods 
4.2.1 Reagents and antibodies  
QIAprep
®
 Miniprep Kit was acquired from Qiagen (Hilden, Germany). 
Dual-luciferase
®
 Reporter Assay System was from Promega (Madison, WI). 
Primary antibodies specific for NF-κB p65, phospho-NF-κB p65 (Ser536), 
IκBα, phospho-IκBα (Ser32), IKKα, IKKβ, phospho-IKKα/β (Ser176/180), 
SAPK/JNK, phospho-SAPK/JNK (Thr183/Tyr185), p44/42, phospho-p44/p42 
(Thr202/Tyr204), p38, phospho-p38 (Thr180/Tyr182) were obtained from Cell 




IgG-conjugated to HRP and goat anti-mouse IgG-conjugated to HRP were 
purchased from Thermo Scientific (Waltham, MA). Alexa Fluor
®
 488 goat 
anti-rabbit IgG (H + L) was from Invitrogen (Eugene, OR). VECTASHIELD
®
 
mounting medium for fluorescence with DAPI H-1200 was obtained from 
Vector Laboratories (Burlingame, CA). PathDetect
®
 pNF-kB-Luc 
Cis-Reporter Plasmids were purchased from Stratagene (Santa Clara, CA). 
pRL-CMV plasmids were from Promega (Madison, WI). GeneJuice
®
 
transfection reagent was from Novagen (Nottingham, UK). Chalcones, ISL 
and PMA were reconstituted in DMSO as stocks and stored in -20 ℃. 
 
4.2.2 Methods  
4.2.2.1 Cell culture and treatment  
MDA-MB-231 cells were cultured as described in Chapter 2 Section 2.2.2.1. 
For experiments involving western blot analysis and immunofluorescence 
microscopy, upon researching 90% to 100% confluency, cells were incubated 
in serum-free RPMI 1640 medium for 12 to 16 h. The cells were then treated 
with the compounds 1 h before being challenged with PMA (80 nM) for 
another 1 h.   
 
4.2.2.2 Preparation of whole cell lysates  






4.2.2.3 Western blot analysis 
Western blot analysis was carried out as described in Chapter 2 Section 
2.2.2.5.  
 
4.2.2.4 NF-κB-dependent luciferase reporter assay 
MDA-MB-231 cells were seeded in 24-well plates and allowed to grow to 60% 
confluency prior to transfection. The concentrations of pNF-κB-Luc and 
pRL-CMV plasmids used were 0.7 μg and 14 ng per well. The amount of 
GeneJuice
®
 transfection reagent, calculated as 3 μl:1μg of DNA, was added to 
serum-free medium in a sterile eppendorf tube and allowed to stand for 5 min. 
Plasmids were then added to the medium mixture and the contents were left to 
stand for 30 min with occasional gentle agitation. 100 μl of the mixture were 
evenly added into each well and the transfected cells were maintained in 5% 
CO2 at 37 ℃ for 24 h. The cells were then incubated in serum-free medium for 
another 12 h to 16 h, after which they were treated with chalcones and ISL for 
1 h, followed by induction with PMA (80 nM) for 10 to 12 h.  
 
The medium was gently removed and the cells were lysed in 100 μl of 1X 
PLB lysis buffer as provided in the kit. 80 μl of Luciferase Assay Reagent II 
(LAR II) reconstituted by resuspending lyophilized Luciferase Assay Substrate 




firefly luciferase activity was read using a Tecan Infinite M200 Microplate 
reader. Renilla luciferase activity was next read following the addition of 80 μl 
of Stop & Glo
®
 Reagent (freshly prepared by adding 1 volume of 50 X Stop & 
Glo
®
 Substrate to 50 volumes of Stop & Glo
®
 Buffer) to each lysate + LAR II 
sample. Fold of induction was expressed as the firefly luciferase activity 
normalized to renilla luciferase activity of each sample over that of 
DMSO-treated group. The data was obtained from three independent 
experiments.            
 
4.2.2.5 Immunofluorescence microscopy  
MDA-MB-231 cells were seeded on a glass cover slip coated with sterile 
poly-L-Lysine. Upon reaching 90% to 100% confluency, the cells were 
changed to serum-free medium for 12 to 16 h, and then treated with chalcones 
for 1 h before being induced with PMA (80 nM) for another 1 h.  
 
After removing the medium, the cells were gently washed with PBS for 5 min 
before fixed in 4% paraformadehyde (PFA) for 10-15 min. The cells were then 
washed three times with PBS (a 5 min interval between each wash) and 
permeabilized in PBS supplemented with 0.2 % Triton X-100 for 10-15 min 
followed by three times washes (a 5 min interval between each wash) in 
PBS-T (PBS with 0.05% Tween 20) and then blocked in PBS-T with 5% 




interval between each wash), the cells were then incubated in rabbit 
anti-NF-κB p65 antibody (4 μl of NF-κB p65 antibody in 10 ml PBS-T with 1% 
Horse serum) for 2 h, followed by probing avoid of light with Alexa Fluor
®
 
488 goat anti-rabbit IgG (H + L) in PBS-T with 1% Horse serum for 1 h. The 
unbounded antibodies were washed away with PBS-T three times (a 5 min 
interval between each wash). The cover slip in each well was then taken out 
with tweezers and mounted gently on a microscope slide with a drop (5-10 μl) 
of VECTASHIELD
®
 mounting medium containing DAPI. The slides were left 
to dry, sealed with nail polish, observed and photographed under Nikon 
Eclipse Ti microscope (Nikon Instruments).         
 
4.2.2.6 Statistical analysis 
Statistical tools used were similar to those adopted in Chapter 2 Section 
2.2.2.6. 
4.3 Results 
4.3.1 Effects of chalcones and ISL on NF-κB transcriptional activity in 
PMA-induced MDA-MB-231 cells  
The promoter region of the MMP-9 gene contains binding sites for 
transcription factor NF-κB (Yan and Boyd, 2007). Meanwhile, NF-κB 
signaling also contributes to the regulations of other MMPs either through 




Therefore, effects of chalcones on the transcriptional activity of NF-κB were 
analyzed using a dual luciferase reporting system. MDA-MB-231 cells 
co-transfected with pNF-κB-Luc and pRL-CMV plasmids were treated with 
PMA (80 nM) with or without the presence of chalcones or ISL. PMA (80 nM) 
induced a marked increase in NF-κB transcriptional activity by over 5-fold 
(column 2 in Figure 4.1), which were suppressed by CC1, CC3, CC7, CC9 
and ISL. Though CC displayed reduction at 10 μM, it induced NF-κB 
transcriptional activity even higher than PMA at 5 μM. Suppression on NF-κB 
transcriptional activity produced by CC3, CC7 and CC9 at 10 μM was 
stronger than that by 10 μM ISL, with CC3 demonstrating the strongest effect 
that decreased the transcriptional activity by almost 3-fold, while CC7 and 
CC9 showed relatively similar efficacies. Interestingly, CC1 demonstrated 
reversed results; although it markedly reduced NF-κB transcriptional activity 






Figure 4.1 Effects of chalcones and ISL on NF-κB transcriptional activity 
in PMA-induced MDA-MB-231 cells. MDA-MB-231 cells co-transfected 
with pNF-κB-Luc and pRL-CMV plasmids for 24 h were pretreated with 
chalcones for 1 h and then exposed to PMA (80 nM) for another 12 to 16 h.  
Luciferase activity was calculated as described in Section 4.2.2.4. Data 
presented as columns was obtained from three independent experiments. 
Standard deviations were shown as bars. † p < 0.01 versus DMSO treated 
group (column 1); * p < 0.05 versus PMA-only group (column 2); ** p < 0.01 
versus PMA-only group (column 2).     
 
4.3.2 Inhibition of NF-κB p65 nuclear translocation by CC7 and CC9 in 
PMA-induced MDA-MB-231 cells  
The most prevalent activated form of NF-κB is a heterodimer consisting of a 
p50 or p52 subunit and p65 (Tak and Firestein, 2001). NF-κB is normally 




p65 subunit is released into the nucleus to initiate target gene transcription 
(Ghosh and Baltimore, 1990; Ghosh and Hayden, 2008). Being the chalcones 
that demonstrated strongest effects in the absence of induction of cytotoxicity, 
CC7 and CC9 had been selected and analyzed using immunocytochemistry to 
examine their possible effects on p65 translocation. DAPI 
(4’6-diamidino-2-phenylindole) is a fluorescence stain that binds to 
double-strand DNA. Upon excitation with ultraviolet (358 nm), its emission 
maximum can be detected at 461 nm through the DAPI filter in the 
microscope (Eclipse Ti, Nikon Instruments), which illuminates the blue color 
and indicates the location and profile of nucleus as displayed in lane 1 in 
Figure 4.2. Alexa Fluor
®
 488 dye is the fluorescence tag conjugated to the 
secondary antibody used in this experiment. Similar to fluorescein 
isothiocyanate (FITC), Alexa Fluor
®
 488 dye is another green-fluorescent dye 
that matches for green fluorescence protein (GFP) filter used for FITC (Ex/Em 
λ: 495 nm/521 nm). Therefore, lane 2 in Figure 4.2 indicated p65 location. 
When images of lane 1 and lane 2 were overlaid, the relative location of p65 
could be observed. In PMA untreated MDA-MB-231 cells (PMA- group, row 
1 in Figure 4.2), p65 was observed to be predominantly located in the 
cytoplasm of unstimulated cells (blue and green color did not overlap in the 
overlaid images). Whereas in the presence of PMA (80 nM), p65 was 
translocated into the nucleus (row 2 in Figure 4.2). Clearly, both CC7 and CC9 








Figure 4.2 Inhibitory effects of CC7 and CC9 on NF-κB p65 nuclear 
translocation in PMA-induced MDA-MB-231 cells. After pretreatment with 
CC7 and CC9 for 1 h, the cells were incubated with PMA (80 nM) for another 





4.3.3 Inhibitory effect of chalcones and ISL on NF-κB p65 
phosphorylation in PMA-induced MDA-MB-231 cells  
Ghosh et al. and Viatour et al. had previously reported that phosphorylation of 
NF-κB p65 at serine 536 was involved in the process p65 nuclear translocation 
(Ghosh and Karin, 2002; Viatour et al., 2005). Therefore, the effects of 
chalcones and ISL on p65 phosphorylation were investigated. As demonstrated 
in Figure 4.3, although total amount of p65 in the cells had stayed unchanged, 
all the chalcones and ISL exhibited reduction in phosphorylated p65 levels 
dose-dependently. Of note, the chalcones had displayed similar amount of 




Figure 4.3 Inhibition of chalcones and ISL on phospho-p65 levels in 
PMA-induced MDA-MB-231 cells. Cell lysates collected upon treatment 
with chalcones and ISL for 1 h and subsequently to PMA (80 nM) for another 
1 h were examined for total p65 and phosphorylated p65 protein levels using 






4.3.4 Suppression of chalcones and ISL on components of the NF-κB 
signaling pathway in PMA-induced MDA-MB-231 cells  
IκBα, the inhibitory protein associated with the inactive form of NF-κB, exists 
in the cytoplasm under normal conditions. The activation and translocation of 
NF-κB is mediated by phosphorylation of IκBα, which is in turn regulated by 
phospho-IKKα/β (Ghosh and Baltimore, 1990). The phospho-IκBα is then 
ubiquitinated and degraded by the 26S proteasome (Chen et al., 1995). 
Induction with PMA (80 nM) increased phospho-IκBα level (panel 1 in Figure 
4.4) and decreased IκBα level (panel 2 in Figure 4.4). Chalcones and ISL 
demonstrated dose-dependent decrease and increase in phospho-IκBα and 
IκBα levels respectively. Interestingly, chalcones had displayed similar 
effectiveness as ISL in suppressing phospho-IκBα, but brought about IκBα 
accumulation to a greater extent than ISL. Chalcones and ISL could also 
suppress phospho-IKKα/β level without affecting total protein level of IKKα 
and IKKβ (panel 3, 4, 5 in Figure 4.4), and the reduction effects appeared to 
be stronger for phospho-IKKβ than that of phospho-IKKα. As compared to 
ISL, the chalcone analogs demonstrated stronger effects in suppressing 








Figure 4.4 Suppression of chalcones and ISL on NF-κB signaling pathway 
in PMA-induced MDA-MB-231 cells. Upon exposure to chalcones and ISL 
for 1 h, the cells were challenged with PMA (80 nM) for another 1 h. Cell 
lysates were subsequently collected and subjected to western blot analysis as 
described in Section 4.2.2.3 and Section 2.2.2.5 in Chapter 2.  
 
4.3.4 Effects of chalcones and ISL on MAPK signaling pathway in 
PMA-induced MDA-MB-231 cells   
MAPK family is the main contributor to the activation of AP-1, which is one 
of the important transcription factors involved in the transcription of several 
MMP gene, including MMP-9, MMP-7 and MMP-13 (Curran and Murray, 
2000; Shaulian and Karin, 2002; Stamenkovic, 2000; Westermarck and Kahari, 
1999). The effects of chalcones and ISL on various components of MAPK and 
phospho-MAPK family members were examined in the following experiments. 




(lane 2 in panel 3 of Figure 4.5) and phospho-p44/42 (ERK) (44 and 42 kDa) 
slightly (lane 2 in panel 5 of Figure 4.5), but markedly stimulated 
phospho-SAPK/JNK (54 and 46 kDa) levels (lane 2 in panel 1 of Figure 4.5). 
However, their respective total protein levels had remained unchanged (panel 
2, 4, 6 of Figure 4.5). Chalcones and ISL decreased phospho-SAPK/JNK 
levels dose-dependently, whereas the effects of chalcones were not as strong 
as that of ISL. For phospho-p38 and phospho-p44/42, no effects could be 
observed for all chalcones. 
   
 
 
Figure 4.5 Effects of chalcones and ISL on MAPK signaling pathway in 
PMA-induced MDA-MB-231 cells. MDA-MB-231 cells were exposed to 
chalcones and ISL for 1 h and then incubated with PMA (80 nM) for another 1 
h and followed by western blot analysis as detailed in section 4.2.2.3 and 





The NF-κB and AP-1 signaling pathways play important roles in regulating 
MMP gene transcription. Tumor invasion and metastasis is at least in part 
mediated through MMPs such as MMP-9, MMP-7 and MMP-13, whose genes 
contain a binding site for AP-1 in their promoter regions. The MMP-9 gene 
also contains the NF-κB binding site in its promoter region (Yan and Boyd, 
2007). The effects of chalcones on the transcriptional activity of NF-κB were 
therefore examined using luciferase reporter gene assays. Similar experiments 
had also been conducted for AP-1, but the transfection efficiency using 
pAP-1-Luc plasmids obtained from the same company were not successful 
(data not shown). Thus more work to optimize transfection efficiency would 
be required for further exploration. As depicted in Figure 4.1, the induction of 
NF-κB transcription by PMA (80 nM) was consistent with previous reports 
(Adams et al., 2010; Cho et al., 2011; Kwon et al., 2009; Ling et al., 2010; 
Ling et al., 2011). CC significantly induced NF-κB transcriptional activity at 
10 μM, and also demonstrated no suppression in previous results of gelatin 
zymography (Figure 2.5 in Chapter 2) and western blotting (Figure 2.6 and 
Figure 2.6 in Chapter 2), suggesting that CC exerted minimal or negligible 
anti-invasive activities as compared to other chalcones. CC1 displayed 
significant suppressive effect on NF-κB luciferase activity at 5 μM, but was 
found less inhibitory at 10 μM. This might be caused by high sensitivity of the 




pRL-CMV (for renilla luciferase activity) and pNF-κB-Luc (for firefly 
luciferase activity) plasmids for CC1 10 μM treatment group. Therefore, 
further repetitions are needed for more reliable data. Nonetheless, based on the 
observed inhibitory effects of chalcones on the NF-κB transcriptional activity, 
it was reasoned that NF-κB inhibition could be one of the mechanisms 
accounting for decrease in MMP-9 mRNA levels (results presented in Figure 
3.6 in Chapter 3).   
 
To understand whether chalcones’ suppressive effects on NF-κB 
transcriptional activity could be contributed by possible effects on different 
components of the NF-κB signaling cascade (summarized in Figure 4.6), 
effects of chalcones on the expression levels of total and phosphorylated forms 
of IκBα and IKK were studied. A decreased in phospho-IKKα/β levels by 
chalcones could in turn result in the inhibition of phospho-IκBα. As 
degradation of IκBα primarily results from IκBα phosphorylation at serine 32 
and serine 36 (Ghosh and Baltimore, 1990), inhibition of IκBα 
phosphorylation may prevent IκBα degradation. As a result, this led to 
suppression of p65 nuclear translocation, followed by reduction in the 
NF-κB-dependent transcription of downstream genes such as MMP-9. Work 
by Ghosh et al. and Viatour et al. had reported that phosphorylation of NF-κB 
p65 at serine 536 was involved in the process p65 nuclear translocation 




had reported that phosphorylation of p65 on Serine 536 might be mediated 
through a non-classic IκBα-independent NF-κB pathway (Sasaki et al., 2005). 
The exact function of the phospho-p65 is therefore still not fully elucidated. 
Nonetheless, given that several studies have demonstrated the reduction of 
phospho-p65 by various compounds possessing anti-invasive potential in 
breast cancer (Ling et al., 2010; Ling et al., 2011; Sathya et al., 2010; Slivova 
et al., 2005), it appeared that the reduction of phospho-p65 might  in some 
way be involved in suppression of NF-κB activity.     
 
Increased tran-activation through AP-1 is achieved largely through 
MAPK-mediated phosphorylation (Figure 4.6). The activated p38 kinase also 
increases the cellular amount of the AP-1 proteins indirectly through 
increasing transcription of c-jun and c-fos promoters (Van den Steen et al., 
2002). Furthermore, MAPK-mediated phosphorylation had also increased the 
trans-activation through AP-1 signaling pathway (Yan and Boyd, 2007). 
Several studies have also reported the regulation of MMP gene expression by 
MAPK-mediated cell signaling (Van den Steen et al., 2002; Westermarck and 
Kahari, 1999). Though AP-1 transfection was not successful in our current 
experimental setup, components of the various MAPK cascades had been 
examined in our study. Chalcones only demonstrated inhibitory effects on 
SAPK/JNK signaling cascade without affecting p38 and p44/42 signaling. 




anti-invasive property through regulating this cascade in breast cancer (Kwon 
et al., 2009). In conclusion, we had obtained results demonstrating that 
chalcones exerted their anti-invasive properties by down-regulating MMP-9 
levels, which in turn was mediated at least in part by their inhibitory effects on 




Figure 4.6 A summary of the proposed molecular mechanism through 
which chalcones inhibit PMA-induced breast carcinoma cell invasion. 
Chalcones suppressed PMA-induced IKKα/β phosphorylation, thereby 
preventing IκBα phosphorylation. As a result, nuclear translocation of p65 and 
transcription of MMP-9 gene were suppressed. By inhibition of MMP-9 
expression and secretion, chalcones exerted anti-invasive properties against 




Chapter 5: General discussion and future work  
5.1 Anti-invasive property  
In summary, in this present study, a total of nine chalcone analogs bearing 
hydroxy, fluorine and/or methoxy substituents were evaluated along with 
unsubstituented parent chalcone and positive control Isoliquiritigenin (ISL) for 
potential anti-invasive effects. Given that MMP-9 plays an important role in 
tumor invasion and angiogenesis, the suppressive effects of these chalcones on 
MMP-9 levels and gelatinolytic activity were screened. Hydroxylated analogs 
CC1 and CC3, as well as their respective methoxylated counterpart analog 
CC7 and CC9, were found to possess greater inhibitory effects on MMP-9 
than other analogs, As chalcones bearing substituents at different positions on 
ring A and/or ring B of the chalcone core structure were not extensively 
synthesized and analyzed in this study, we had not attempted to discuss or 
conclude in detail the structure-activity relationship governing anti-invasive 
activity of chalcones. Down-regulation of MMP-9 levels by chalcones was 
found to be mediated through inhibition of NF-κB and SAPK/JNK signaling 
pathways. Taken together, we concluded that hydroxylated and methoxylated 
chalcones at the ortho position on ring A exhibited potent anti-invasive effects, 
with the methoxylated analogs CC7 and CC9 possessing low cytotoxicities at 
the same time. Therefore, CC7 and CC9, as our potential candidate for 




5.2 Future work 
5.2.1 Breast cell lines  
The MDA-MB-231 cell line is one of the most common invasive breast cancer 
cell line used in cell-based anti-invasive studies, while MCF-7 cells are less 
invasive but have also been used in studies for similar objectives. These cell 
lines may not possess the full spectrum of MMPs and MMP activities that in 
vivo primary tumors and metastases would possess, which may thus limit the 
use of them to elucidate the complete (if any) anti-invasive profile of 
chalcones. More invasive breast cancer cell lines such as MDA-MB-436 cells, 
MDA-MB-468 cells, TMD-231 or TMD-436 cells will be required in future 
work. Besides breast carcinoma cells, non-tumorigenic breast cell lines should 
also be included to verify the selectivity of the compounds.  
5.2.2 New methodologies 
In addition to the wound healing assay that had been conducted in this study to 
examine the inhibitory effects of cell migration, the cell invasion assay 
(Matrigel
TM
 invasion assay) should also be conducted to evaluate the 
efficacies of chalcones on suppressing tumor cell invasion. Quantitative 
software should also be adopted to analyze the qualitative results for 
validation.    
5.2.3 Analysis of related proteins 




between the levels of uPA in cell lysates and conditioned medium. 
Experiments for further optimization would need to be conducted in the future. 
In addition, the possible inhibitory effects of chalcones on uPAR, TIMP-1 and 
TIMP-2 are proposed to be investigated in future work.  
5.2.4 AP-1 signaling pathway 
The transfection efficiency of AP-1 plasmids in luciferase gene reporter assays 
had been low through the duration of this project. This would need to be 
further optimized in our future work. Furthermore, the effects of chalcones on 
downstream proteins c-jun and c-fos of the AP-1 signaling pathway will be 
examined.  
5.2.5 Exploration of exact molecular targets of chalcones 
Although CC1, CC3, CC7 and CC9 were found to block the phosphorylation 
of IKK, the exact mechanisms underlying this down-regulation are still 
unknown. The ubiquitin pathway has been reported to activate IKK 
phosphorylation (Chen, 2012), but the nature of IKK phosphorylation still 
needs to be explored. Elucidation of the exact molecular target(s) of chalcones 
may contribute to a better understanding of the anti-invasive nature of 
chalcones and also provide important information for the mechanism of IKK 
phosphorylation in NF-κB signaling. Furthermore, PKC signaling pathway 
should also be included as it serves as the upstream of NF-κB and MAPK 




pathways than MAPK pathways, it is possible that they may affect mediators 
in PKC pathways that more likely regulate NF-κB rather than MAPK 
pathways (Lallena et al., 1999). It is also possible that they might target at 
different isotypes of PKC which predominantly regulate through NF-κB 
pathways (Griner and Kazanietz, 2007).    
5.2.6 In vivo studies  
Our study had demonstrated that CC7 and CC9 possessed potent anti-invasive 
activities against MDA-MB-231 and MCF-7 cells in the absence of significant 
cytotoxicity. However, it is still unknown whether they are also effective in in 
vivo metastatic tumor models. Therefore, the in vivo anti-metastatic efficacies 
of these chalcones need to be evaluated in future work. As a first step, 
pharmacokinetic profiling of CC7 and CC9 had been conducted by Dr. Lin 
Haishu (Department of Pharmacy, NUS) using rat models. Both lead chalcone 
analogs were found to undergo fast clearance, with CC7 found to have oral 
bioavailability (details of pharmacokinetic profiles of CC7 and CC9 
highlighted in Appendix II). Given the acceptable pharmacokinetics properties 
of chalcones, this class of compounds is certainly warranted for further in vivo 





Achanta, G., Modzelewska, A., Feng, L., Khan, S.R., Huang, P. (2006). A boronic chalcone 
derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol 
Pharmacol, 70, 426-433. 
Adams, L.S., Phung, S., Yee, N., Seeram, N.P., Li, L., Chen, S. (2010). Blueberry Phytochemicals 
Inhibit Growth and Metastatic Potential of MDA-MB-231 Breast Cancer Cells through 
Modulation of the Phosphatidylinositol 3-Kinase Pathway. Cancer Research, 70, 3594-3605. 
Aggarwal, S., Ichikawa, H., Takada, Y., Sandur, S.K., Shishodia, S., Aggarwal, B.B. (2006). 
Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and 
Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt 
Activation. Molecular Pharmacology, 69, 195-206. 
Anto, R.J., Sukumaran, K., Kuttan, G., Rao, M.N.A., Subbaraju, V., Kuttan, R. (1995). Anticancer 
and antioxidant activity of synthetic chalcones and related compounds. Cancer Letters, 97, 
33-37. 
Baker, A.H., Edwards, D.R., Murphy, G. (2002). Metalloproteinase inhibitors: biological actions 
and therapeutic opportunities. Journal of Cell Science, 115, 3719-3727. 
Batovska, D.I., Todorova, I.T.o.d.o.r.o.v.a. (2010). Trends in Utilization of the Pharmacological 
Potential of Chalcones. Current Clinical Pharmacology, 5, 1-29. 
Baum, O., Hlushchuk, R., Forster, A., Greiner, R., Clezardin, P., Zhao, Y., Djonov, V., Gruber, G. 
(2007). Increased invasvie potential and up-regulation of MMP-2 in MDA-MB-231 breast 
cancer cells expressing the beta3 integrin subunit. International Journal of Oncology, 30, 
325-332. 
Bellosta, S., Via, D., Canavesi, M., Pfister, P., Fumagalli, R., Paoletti, R., Bernini, F. (1998). 
HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 18, 1671-1678. 
Benelli, R., Venè, R., Ciarlo, M., Carlone, S., Barbieri, O., Ferrari, N. (2012). The AKT/NF-κB 
inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming 
chemoresistance and cell infiltration. Biochemical Pharmacology, 83, 1634-1642. 
Bernardo, M.M., Fridman, R. (2003). TIMP-2 (tissue inhibitor of metalloproteinase-2) 
regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after 
pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J, 374, 739-745. 
Bond, M., Chase, A.J., Baker, A.H., Newby, A.C. (2001). Inhibition of transcription factor NF-κB 
reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. 
Cardiovascular Research, 50, 556-565. 
Bourguignon, L.Y.W., Gunja-Smith, Z., Iida, N., Zhu, H.B., Young, L.J.T., Muller, W.J., Cardiff, R.D. 
(1998). CD44v3,8–10 is involved in cytoskeleton-mediated tumor cell migration and matrix 
metalloproteinase (MMP-9) association in metastatic breast cancer cells. Journal of Cellular 
Physiology, 176, 206-215. 
Boyd, M.R., Paull, K.D. (1995). Some practical considerations and applications of the national 





Brinckerhoff, C.E., Matrisian, L.M. (2002). Matrix metalloproteinases: a tail of a frog that 
became a prince. Nat Rev Mol Cell Biol, 3, 207-214. 
Brooks, P.C., Strömblad, S., Sanders, L.C., von Schalscha, T.L., Aimes, R.T., Stetler-Stevenson, 
W.G., Quigley, J.P., Cheresh, D.A. (1996). Localization of Matrix Metalloproteinase MMP-2 to 
the Surface of Invasive Cells by Interaction with Integrin αvβ3. Cell, 85, 683-693. 
Burrage, P.S., Mix, K.S., Brinckerhoff, C.E. (2006). Matrix Metalloproteinases: Role In Arthritis. 
Frontiers in Bioscience 11, 529-543. 
Calliste, C., Le Bail, J., Trouillas, P., Pouget, C., Habrioux, G., Chulia, A., Duroux, J. (2001). 
Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. 
Anticancer Res, 21, 3949-3956. 
Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., Mitchell, J.B. (1987). Evaluation of a 
Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity 
Testing. Cancer Research, 47, 936-942. 
Cavallaro, U., Christofori, G. (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in 
cancer. Nat Rev Cancer, 4, 118-132. 
Cavigelli, M., Dolfi, F., Claret, F.o.-X., Karin, M. (1995). Induction of c-fos expression through 
JNK-mediated TCF/Elk-1 phosphorylation. The EMBO Journal, 14, 5957-5964. 
Chakraborti, S., Mandal, M., Das, S., Mandal, A., Chakraborti, T. (2003). Regulation of matrix 
metalloproteinases: An overview. Molecular and Cellular Biochemistry, 253, 269-285. 
Chan, O., Stewart, B. (1996). Physicochemical and drug-delivery considerations for oral drug 
bioavailability. Drug Discov Today, 1, 461-473. 
Chandler, W.L., Levy, W.C., Stratton, J.R. (1995). The Circulatory Regulation of TPA and UPA 
Secretion, Clearance, and Inhibition During Exercise and During the Infusion of Isoproterenol 
and Phenylephrine. Circulation, 92, 2984-2994. 
Chang, L., Karin, M. (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37-40. 
Chen, Z., Hagler, J., Palombella, V.J., Melandri, F., Scherer, D., Ballard, D., Maniatis, T. (1995). 
Signal-induced site-specific phosphorylation targets I kappa B alpha to the 
ubiquitin-proteasome pathway. Genes & Development, 9, 1586-1597. 
Chen, Z.J. (2012). Ubiquitination in signaling to and activation of IKK. Immunological Reviews, 
246, 95-106. 
Cheng, Z.-J., Lin, C.-N., Hwang, T.-L., Teng, C.-M. (2001). Broussochalcone A, a potent 
antioxidant and effective suppressor of inducible nitric oxide synthase in 
lipopolysaccharide-activated macrophages. Biochemical Pharmacology, 61, 939-946. 
Cho, S., Kim, S., Jin, Z., Yang, H., Han, D., Baek, N.-I., Jo, J., Cho, C.-W., Park, J.-H., Shimizu, M., 
Jin, Y.-H. (2011). Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of 
GABAA receptors and shows hypnotic effects. Biochemical and Biophysical Research 
Communications, 413, 637-642. 
Chung, T.-W., Moon, S.-K., Lee, Y.-C., Kim, J.-G., Ko, J.-H., Kim, C.-H. (2002). Enhanced 
expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Archives 
of Biochemistry and Biophysics, 408, 147-154. 
Clark, I.M., Swingler, T.E., Sampieri, C.L., Edwards, D.R. (2008). The regulation of matrix 
metalloproteinases and their inhibitors. The International Journal of Biochemistry &amp; Cell 
Biology, 40, 1362-1378. 




(1996). Combined overexpression of urokinase, urokinase receptor, and plasminogen 
activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical 
comparison of normal, benign, and malignant breast tissues. Cancer, 77, 1079-1088. 
Coussens, L.M., Raymond, W.W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., 
Caughey, G.H., Hanahan, D. (1999). Inflammatory mast cells up-regulate angiogenesis during 
squamous epithelial carcinogenesis. Genes & Development, 13, 1382-1397. 
Cunha, G.M.d.A., Fontenele, J.B., Nobre Júnior, H.V., de Sousa, F.C.M., Silveira, E.R., Nogueira, 
N.A.P., de Moraes, M.O., Viana, G.S.B., Costa-Lotufo, L.V. (2003). Cytotoxic Activity of 
Chalcones Isolated from Lonchocarpus Sericeus (Pocr.) Kunth. Phytotherapy Research, 17, 
155-159. 
Curran, S., Murray, G.I. (2000). Matrix metalloproteinases: molecular aspects of their roles in 
tumour invasion and metastasis. European Journal of Cancer, 36, 1621-1630. 
Danø, K., Andreasen, P., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L., Skriver, L. (1985). 
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res, 44, 139-266. 
Das, S., Lin, H., Ho, P., Ng, K. (2008). The Impact of Aqueous Solubility and Dose on the 
Pharmacokinetic Profiles of Resveratrol. Pharmaceutical Research 25, 2593-2600. 
Daschner, P.J., Ciolino, H.P., Plouzek, C.A., Yeh, G.C. (1999). Increased AP-1 activity in drug 
resistant human breast cancer MCF-7 cells. Breast Cancer Research And Treatment, 53, 
229-240. 
De Vicente, J.C., Lequerica-Fernández, P., Santamaría, J., Fresno, M.F. (2007). Expression of 
MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor 
invasion and prognosis. Journal of Oral Pathology & Medicine, 36, 415-424. 
De Vincenzo, R., Ferlini, C., Distefano, M., Gaggini, C., Riva, A., Bombardelli, E., Morazzoni, P., 
Valenti, P., Belluti, F., Ranelletti, F.O., Mancuso, S., Scambia, G. (2000). In vitro evaluation of 
newly developed chalcone analogues in human cancer cells. Cancer Chemotherapy and 
Pharmacology, 46, 305-312. 
Dell'Eva, R., Ambrosini, C., Vannini, N., Piaggio, G., Albini, A., Ferrari, N. (2007). AKT/NF-κB 
inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. 
Cancer, 110, 2007-2011. 
Deng, J., Kelley, J.A., Barchi, J.J., Sanchez, T., Dayam, R., Pommier, Y., Neamati, N. (2006). 
Mining the NCI antiviral compounds for HIV-1 integrase inhibitors. Bioorganic &amp; 
Medicinal Chemistry, 14, 3785-3792. 
Denizot, F., Lang, R. (1986). Rapid colorimetric assay for cell growth and survival: 
Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. 
Journal of Immunological Methods, 89, 271-277. 
Di Carlo, G., Mascolo, N., Izzo, A.A., Capasso, F. (1999). Flavonoids: Old and new aspects of a 
class of natural therapeutic drugs. Life Sciences, 65, 337-353. 
Dinkova-Kostova, A.T., Abeygunawardana, C., Talalay, P. (1998). Chemoprotective Properties 
of Phenylpropenoids, Bis(benzylidene)cycloalkanones, and Related Michael Reaction 
Acceptors:   Correlation of Potencies as Phase 2 Enzyme Inducers and Radical Scavengers†. 
Journal of Medicinal Chemistry, 41, 5287-5296. 
Dinkova-Kostova, A.T., Massiah, M.A., Bozak, R.E., Hicks, R.J., Talalay, P. (2001a). Potency of 
Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis 




Sciences, 98, 3404-3409. 
Dinkova-Kostova, A.T., Massiah, M.A., Bozak, R.E., Hicks, R.J., Talalay, P. (2001b). Potency of 
Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis 
depends on their reactivity with sulfhydryl groups. PNAS, 98, 3403-3409. 
Dobson, C.M. (2004). Chemical space and biology. Nature, 432, 824-828. 
Ducki, S. (2009). Antimitotic chalcones and related compounds as inhibitors of tubulin 
assembly. Anticancer Agents Med Chem, 9, 336-347. 
Duffy, M., Maguire, T., Hill, A., McDermott, E., O'Higgins, N. (2000). Metalloproteinases: role 
in breast carcinogenesis, invasion and metastasis. Breast Cancer Res, 2, 252-257. 
E, L., R, G., E, S., J, J., H, W., D, B. (1996). Regulation of urokinase-type plasminogen activator 
expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J 
Cell Biochem, 61, 430-443. 
Edwards, M., Stemerick, D., Sunkara, S. (1988). Chalcone derivatives useful in controlling 
growth of tumor tissue and their preparation. European Patent Application EP 
288, 794. 
Edwards, M.L., Stemerick, D.M., Sunkara, P.S. (1990). Chalcones: a new class of antimitotic 
agents. Journal of Medicinal Chemistry, 33, 1948-1954. 
Ellerbroek, S.M., Stack, M.S. (1999). Membrane associated matrix metalloproteinases in 
metastasis. BioEssays, 21, 940-949. 
Fan, Z., Yang, H., Bau, B., Söder, S., Aigner, T. (2006). Role of mitogen-activated protein 
kinases and NFκB on IL-1β-induced effects on collagen type II, MMP-1 and 13 mRNA 
expression in normal articular human chondrocytes. Rheumatology International, 26, 
900-903. 
Farina, A.R., Coppa, A., Tiberio, A., Tacconelli, A., Turco, A., Colletta, G., Gulino, A., Mackay, 
A.R. (1998). Transforming growth factor-β1 enhances the invasiveness of human 
MDA-MB-231 breast cancer cells by up-regulating urokinase activity. International Journal of 
Cancer, 75, 721-730. 
Forsyth, C.B., Cole, A., Murphy, G., Bienias, J.L., Im, H.-J., Richard F. Loeser, J. (2006). 
Increased Matrix Metalloproteinase-13 Production With Aging by Human Articular 
Chondrocytes in Response to Catabolic Stimuli. J Gerontol A Biol Sci Med Sci, 60, 1118-1124. 
Fridman, R., Toth, M., Peña, D., Mobashery, S. (1995). Activation of Progelatinase B (MMP-9) 
by Gelatinase A (MMP-2). Cancer Research, 55, 2548-2555. 
Friedl, P., Wolf, K. (2003). Tumour-cell invasion and migration: diversity and escape 
mechanisms. Nat Rev Cancer, 3, 362-374. 
Fuchs-Tarlovsky, V. (2012). Role of antioxidants in cancer therapy. Nutrition, Epub ahead of 
print. 
Geiger, T.R., Peeper, D.S. (2009). Metastasis mechanisms. Biochimica et Biophysica Acta (BBA) 
- Reviews on Cancer, 1796, 293-308. 
Ghosh, S., Baltimore, D. (1990). Activation in vitro of NF-[kappa]B" by phosphorylation of its 
inhibitor I[kappa]B". Nature, 344, 678-682. 
Ghosh, S., Hayden, M.S. (2008). New regulators of NF-[kappa]B in inflammation. Nat Rev 
Immunol, 8, 837-848. 
Ghosh, S., Karin, M. (2002). Missing Pieces in the NF-κB Puzzle. Cell, 109, S81-S96. 




healing. The International Journal of Biochemistry &amp; Cell Biology, 40, 1334-1347. 
Go, M.L., Wu, X., Liu, X.L. (2005). Chalcones: An Update on Cytotoxic and Chemoprotective 
Properties. Current Medicinal Chemistry, 12, 483-499. 
Griner, E.M., Kazanietz, M.G. (2007). Protein kinase C and other diacylglycerol effectors in 
cancer. Nat Rev Cancer, 7, 281-294. 
Guo, W., Giancotti, F.G. (2004). Integrin signalling during tumour progression. Nat Rev Mol 
Cell Biol, 5, 816-826. 
Gutteridge, J., Halliwell, B. (1992). Comments on review of Free Radicals in Biology and 
Medicine, second edition, by Barry Hlliwell and John M.C. Gutteridge. Free Radic Biol Med, 12, 
93-95. 
Han, Y.-P., Nien, Y.-D., Garner, W.L. (2002). Tumor Necrosis Factor-α-induced Proteolytic 
Activation of Pro-matrix Metalloproteinase-9 by Human Skin Is Controlled by 
Down-regulating Tissue Inhibitor of Metalloproteinase-1 and Mediated by Tissue-associated 
Chymotrypsin-like Proteinase. Journal of Biological Chemistry, 277, 27319-27327. 
Han, Y., Riwanto, M., Go, M.-L., Rachel Ee, P.L. (2008). Modulation of breast cancer resistance 
protein (BCRP/ABCG2) by non-basic chalcone analogues. European Journal of Pharmaceutical 
Sciences, 35, 30-41. 
Hanahan, D., Weinberg, Robert A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 
144, 646-674. 
Hanemaaijer, R., Koolwijk, P., Clercq, L.l., Vree, W.J.d., Hinsbergh, V.W.v. (1993). Regulation of 
matrix metalloproteinase expression in human vein and microvascular endothelial cells. 
Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J, 296, 
803-809. 
Hashimoto, Y., Kagechika, H., Kawachi, E., Shudo, K. (1987). New-type inducers of 
differentiation of HL-60 leukemia cells suppress c-myc expression. Chem Pharm Bull, 35, 
3190-3194. 
Hayes, J., McLellan, L. (1999). Glutathione and glutathione-dependent enzymes represent a 
co-ordinately regulated defence against oxidative stress. Free Radical Research, 31, 273-300. 
Heikkilä, P., Teronen, O., Moilanen, M., Konttinen, Y.T., Hanemaaijer, R., Laitinen, M., Maisi, P., 
van der Pluijm, G., Bartlett, J.D., Salo, T., Sorsa, T. (2002). Bisphosphonates inhibit 
stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and 
enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion 
and migration of human malignant and endothelial cell lines. Anti-Cancer Drugs, 13, 245-254. 
Heiple, J., Ossowski, L. (1986). Human neureophil plasminogen activator is localized in 
specific granules and is translocated to the cell surface by exocytosis. J. Exp.Med, 164, 
826-840. 
Hsu, Y.-L., Chia, C.-C., Chen, P.-J., Huang, S.-E., Huang, S.-C., Kuo, P.-L. (2009). Shallot and 
licorice constituent isoliquiritigenin arrests cell cycle progression and induces apoptosis 
through the induction of ATM/p53 and initiation of the mitochondrial system in human 
cervical carcinoma HeLa cells. Molecular Nutrition & Food Research, 53, 826-835. 
Hsu, Y.L., Kuo, P.L., Tzeng, W.S., Lin, C.C. (2006). Chalcone inhibits the proliferation of human 
breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food and 
Chemical Toxicology, 44, 704-713. 




Beug, H., Wirth, T. (2004). NF-κB is essential for epithelial-mesenchymal transition and 
metastasis in a model of breast cancer progression. J Clin Invest, 114, 569-581. 
Hurst, S., Loi, C., Brodfuehrer, J., El-Kattan, A. (2007). Impact of physiological, physicochemical 
and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral 
bioavailability of rats and humans. Expert Opin Drug Metab Toxicol, 3, 469-489. 
Jiang, Y.L., Liu, Z.P. (2011). Natural Products as Anti-Invasive and Anti-Metastatic Agents. 
Current Medicinal Chemistry, 18, 808-829. 
Joshi, A., Li, X., Nimrod, A., elSohly, H., Walker, L., Clark, A. (2001). Dihydrochalcones from 
Piper longicaudatum. Planta Med, 67, 186-188. 
Juven-Gershon, T., Oren, M. (1999). Mdm2: the ups and downs. Mol Med, 5, 71-83. 
Kamal, A., Ramakrishna, G., Raju, P., Viswanath, A., Janaki Ramaiah, M., Balakishan, G., 
Pal-Bhadra, M. (2010). Synthesis and anti-cancer activity of chalcone linked imidazolones. 
Bioorganic &amp; Medicinal Chemistry Letters, 20, 4865-4869. 
Karin, M. (1995). The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases. 
Journal of Biological Chemistry, 270, 16483-16486. 
Karin, M., Hawkins, P.T. (1996). The Regulation of AP-1 Activity by Mitogen-Activated Protein 
Kinases [and Discussion]. Philosophical Transactions of the Royal Society of London. Series B: 
Biological Sciences, 351, 127-134. 
Katsori, A.-M., Hadjipavlou-Litina, D. (2011). Recent progress in therapeutic applications of 
chalcones. Expert Opinion on Therapeutic Patents, 21, 1575-1596. 
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D.X., Zhang, X.H.F., Norton, L., Massagué, J. 
(2009). Tumor Self-Seeding by Circulating Cancer Cells. Cell, 139, 1315-1326. 
Knäuper, V., Smith, B., López-Otin, C., Murphy, G. (1997). Activation of Progelatinase B 
(proMMP-9) by Active Collagenase-3 (MMP-13). European Journal of Biochemistry, 248, 
369-373. 
Ko, H.-H., Tsao, L.-T., Yu, K.-L., Liu, C.-T., Wang, J.-P., Lin, C.-N. (2003). Structure–activity 
relationship studies on chalcone derivatives: the potent inhibition of chemical mediators 
release. Bioorganic &amp; Medicinal Chemistry, 11, 105-111. 
Kondapaka, S.B., Fridman, R., Reddy, K.B. (1997). Epidermal growth factor and amphiregulin 
up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. International 
Journal of Cancer, 70, 722-726. 
Kumar, S.K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N.E., Khan, S.R. (2003). Design, 
Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents. Journal 
of Medicinal Chemistry, 46, 2813-2815. 
Kundu, J.K., Surh, Y.-J. (2008). Inflammation: Gearing the journey to cancer. Mutation 
Research/Reviews in Mutation Research, 659, 15-30. 
Kwon, G., Cho, H., Chung, W., Park, K., Moon, A., Park, J. (2009). Isoliquiritigenin inhibits 
migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 
signaling. J Nutr Biochem, 20, 663-676. 
Lallena, M.-J., Diaz-Meco, M.T., Bren, G., Payá, C.V., Moscat, J. (1999). Activation of IκB Kinase 
β by Protein Kinase C Isoforms. Molecular and Cellular Biology, 19, 2180-2188. 
Lampugnani, M.G. (1999). Cell migration into a wounded area in vitro. Methods in molecular 
biology, 96, 177-182. 




Distribution of urokinase-type plasminogen activation immunoreactivity in the mouse. The 
Journal of Cell Biology, 98, 894-903. 
Le Bail, J.-C., Pouget, C., Fagnere, C., Basly, J.-P., Chulia, A.-J., Habrioux, G. (2001). Chalcones 
are potent inhibitors of aromatase and 17β-hydroxysteroid dehydrogenase activities. Life 
Sciences, 68, 751-761. 
Lee, J.-S., Surh, Y.-J. (2005). Nrf2 as a novel molecular target for chemoprevention. Cancer 
Letters, 224, 171-184. 
Legrand, C., Polette, M., Tournier, J.-M., de Bentzmann, S., Huet, E., Monteau, M., Birembaut, 
P. (2001). uPA/Plasmin System-Mediated MMP-9 Activation Is Implicated in Bronchial 
Epithelial Cell Migration. Experimental Cell Research, 264, 326-336. 
Lin, C.-W., Hou, W.-C., Shen, S.-C., Juan, S.-H., Ko, C.-H., Wang, L.-M., Chen, Y.-C. (2008). 
Quercetin inhibition of tumor invasion via suppressing PKCδ/ERK/AP-1-dependent matrix 
metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis, 29, 1807-1815. 
Lin, H.-S., Choo, Q.-Y., Ho, P.C. (2010a). Quantification of oxyresveratrol analog trans-2,4,3′,5′
-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical 
pharmacokinetic study. Biomedical Chromatography, 24, 1373-1378. 
Lin, H.-S., Ho, P.C. (2009). A rapid HPLC method for the quantification of 3,5,4 ′
-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. 
Journal of Pharmaceutical and Biomedical Analysis, 49, 387-392. 
Lin, H.-s., Ho, P.C. (2011). Preclinical pharmacokinetic evaluation of resveratrol trimethyl 
ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and 
repeated dosing on oral bioavailability. Journal of Pharmaceutical Sciences, 100, 4491-4500. 
Lin, H.-S., Spatafora, C., Tringali, C., Ho, P.C. (2012). Determination of trans-2,4,3′,4′,5′
-pentamethoxystilbene in rat plasma and its application to a pharmacokinetic study. Journal 
of Pharmaceutical and Biomedical Analysis, 57, 94-98. 
Lin, H.-S., Tringali, C., Spatafora, C., Wu, C., Ho, P.C. (2010b). A simple and sensitive HPLC-UV 
method for the quantification of piceatannol analog trans-3,5,3′,4′-tetramethoxystilbene in 
rat plasma and its application for a pre-clinical pharmacokinetic study. Journal of 
Pharmaceutical and Biomedical Analysis, 51, 679-684. 
Lin, H.-S., Yue, B.-D., Ho, P.C. (2009). Determination of pterostilbene in rat plasma by a simple 
HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomedical 
Chromatography, 23, 1308-1315. 
Lin, H.-S., Zhang, W., Go, M.L., Choo, Q.-Y., Ho, P.C. (2010c). Determination of Z-3,5,4′
-trimethoxystilbene in rat plasma by a simple HPLC method: Application in a pre-clinical 
pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 53, 693-697. 
Lin, H.-S., Zhang, W., Go, M.L., Tringali, C., Spatafora, C., Ho, P.C. (2011). Quantification of 
trans-3,4,5,4′-Tetramethoxystilbene in Rat Plasma by HPLC: Application to Pharmacokinetic 




Lin, H., Tringali, C., Spatafora, C., Choo, Q., Ho, P. (2010d). LC determination of 
trans-3,5,3',4',5'-pentamethoxystilbene in rat plasma. Chromatographia, 72, 827-832. 
Ling, H., Yang, H., Tan, S.H., Chui, W.K., Chew, E.H. (2010). 6-Shogaol, an active constituent of 
ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression 
via blockade of nuclear factor-κB activation. British Journal of Pharmacology, 161, 1763-1777. 
Ling, H., Zhang, Y., KY, N., EH, C. (2011). Pachymic acid impairs breast cancer cell invasion by 
suppressing nuclear factor-jB-dependent matrix metalloproteinase-9 expression. Breast 
Cancer Res Treat, 126, 609-620. 
Liotta, L.A., Stetler-Stevenson, W.G. (1991). Tumor Invasion and Metastasis: An Imbalance of 
Positive and Negative Regulation. Cancer Research, 51, 5054s-5059s. 
Lipinski, C., Hopkins, A. (2004). Navigating chemical space for biology and medicine. Nature, 
432, 855-861. 
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. (2001). Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Advanced Drug Delivery Reviews, 46, 3-26. 
Liu, X.-L., Tee, H.-W., Go, M.-L. (2008). Functionalized chalcones as selective inhibitors of 
P-glycoprotein and breast cancer resistance protein. Bioorganic &amp; Medicinal Chemistry, 
16, 171-180. 
London, C.A., Sekhon, H.S., Arora, V., Stein, D.A., Iversen, P.L., Devi, G.R. (2003). A novel 
antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion 
and tumorigenicity. Cancer Gene Therapy, 10, 823-832. 
Maggiolini, M., Statti, G., Vivacqua, A., Gabriele, S., Rago, V., Loizzo, M., Menichini, F., Amdo, 
S. (2002). Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer 
cells. J Steroid Biochem Mol Biol, 82, 315-322. 
Markaverich, B.M., Gregory, R.R., Alejandro, M., Kittrell, F.S., Medina, D., Clark, J.H., Varma, 
M., Varma, R.S. (1990). Methyl p-Hydroxyphenyllactate and Nuclear Type II Binding Sites in 
Malignant Cells: Metabolic Fate and Mammary Tumor Growth. Cancer Research, 50, 
1470-1478. 
Massagué, J. (2008). TGFβ in Cancer. Cell, 134, 215-230. 
Mauviel, A. (1993). Cytokine regulation of metalloproteinase gene expression. Journal of 
Cellular Biochemistry, 53, 288-295. 
Menashi, S., Fridman, R., Desrivieres, S., Lu, H.E., Legrand, Y., Soria, C. (1994). Regulation of 
92-kDa Gelatinase B Activity in the Extracellular Matrix by Tissue Kallikrein. Annals of the 
New York Academy of Sciences, 732, 466-468. 
Mercurio, F., Manning, A.M. (1999). Multiple signals converging on NF-κB. Current Opinion in 
Cell Biology, 11, 226-232. 
Miranda, C.L., Aponso, G.L.M., Stevens, J.F., Deinzer, M.L., Buhler, D.R. (2000). Prenylated 
chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1c1c7 cells. 
Cancer Letters, 149, 21-29. 
Mojzis, J., Varinska, L., Mojzisova, G., Kostova, I., Mirossay, L. (2008). Antiangiogenic effects of 
flavonoids and chalcones. Pharmacological Research, 57, 259-265. 
Monostory, K., Tamási, V., Vereczkey, L., Perjési, P. (2003). A study on CYP1A inhibitory action 




chalcone analogues. Toxicology, 184, 203-210. 
Mosmann, T. (1983). Rapid colorimetric aasay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63. 
Mukherjee, S., Kumar, V., Prasad, A.K., Raj, H.G., Bracke, M.E., Olsen, C.E., Jain, S.C., Parmar, 
V.S. (2001). Synthetic and biological activity evaluation studies on novel 1,3-diarylpropenones. 
Bioorganic &amp; Medicinal Chemistry, 9, 337-345. 
Murphy, G., Nagase, H. (2008). Progress in matrix metalloproteinase research. Molecular 
Aspects of Medicine, 29, 290-308. 
Murray, G.I., Duncan, M.E., O'Neil, P., McKay, J.A., Melvin, W.T., Fothergill, J.E. (1998). Matrix 
metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. The Journal of 
Pathology, 185, 256-261. 
Nagase, H., Woessner, J.F. (1999). Matrix Metalloproteinases. Journal of Biological Chemistry, 
274, 21491-21494. 
Nakshatri, H., Bhat-Nakshatri, P., Martin, D.A., Goulet, R.J., Sledge, G.W. (1997). Constitutive 
activation of NF-kappaB during progression of breast cancer to hormone-independent 
growth. Molecular and Cellular Biology, 17, 3629-3639. 
Nam, N.-H., Kim, Y., You, Y.-J., Hong, D.-H., Kim, H.-M., Ahn, B.-Z. (2003). Cytotoxic 2′,5′
-dihydroxychalcones with unexpected antiangiogenic activity. European Journal of Medicinal 
Chemistry, 38, 179-187. 
Nelson, A.R., Fingleton, B., Rothenberg, M.L., Matrisian, L.M. (2000). Matrix 
Metalloproteinases: Biologic Activity and Clinical Implications. Journal of Clinical Oncology, 18, 
1135. 
Nerlov, C., Rørth, P., Blasi, F., Johnsen, M. (1991). Essential AP-1 and PEA3 binding elements in 
the human urokinase enhancer display cell type-specific activity. Oncogene, 6, 1583-1593. 
Ni, L., Meng, C.Q., Sikorski, J.A. (2004). Recent advances in therapeutic chalcones. Expert 
Opinion on Therapeutic Patents, 14, 1669-1691. 
Nowakowska, Z. (2007). A review of anti-infective and anti-inflammatory chalcones. European 
Journal of Medicinal Chemistry, 42, 125-137. 
Okada, Y., Gonoji, Y., Naka, K., Tomita, K., Nakanishi, I., Iwata, K., Yamashita, K., Hayakawa, T. 
(1992). Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 
human fibrosarcoma cells. Purification and activation of the precursor and enzymic 
properties. Journal of Biological Chemistry, 267, 21712-21719. 
Oladipo, O., Coyle, V., McAleer, J.J., McKenna, S. (2012). Achieving Optimal Dose Intensity 
with Adjuvant Chemotherapy in Elderly Breast Cancer Patients: A 10-Year Retrospective Study 
in a UK Institution. The Breast Journal, 18, 16-22. 
Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., Vogelstein, B. (1992). Amplification of a 
gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83. 
Oprea, T.I., Davis, A.M., Teague, S.J., Leeson, P.D. (2001). Is There a Difference between Leads 
and Drugs? A Historical Perspective. Journal of Chemical Information and Computer Sciences, 
41, 1308-1315. 
Ossowski, L., Aguirre-Ghiso, J.A. (2000). Urokinase receptor and integrin partnership: 
coordination of signaling for cell adhesion, migration and growth. Current Opinion in Cell 




Overall, C.M., Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for 
the post-trial era. Nat Rev Cancer, 2, 657-672. 
Park, W.-H., Kim, S.-H., Kim, C.-H. (2005). A new matrix metalloproteinase-9 inhibitor 
3,4-dihydroxycinnamic acid (caffeic acid) from methanol extract of Euonymus alatus: isolation 
and structure determination. Toxicology, 207, 383-390. 
Parmar, V.S., Sharma, N.K., Husain, M., Watterson, A.C., Kumar, J., Samuelson, L.A., Cholli, A.L., 
Prasad, A.K., Kumar, A., Malhotra, S., Kumar, N., Jha, A., Singh, A., Singh, I., Himanshu, Vats, A., 
Shakil, N.A., Trikha, S., Mukherjee, S., Sharma, S.K., Singh, S.K., Jha, H.N., Olsen, C.E., Stove, 
C.P., Bracke, M.E., Mareel, M.M. (2003). Synthesis, characterization and in vitro anti-invasive 
activity screening of polyphenolic and heterocyclic compounds. Bioorganic &amp; Medicinal 
Chemistry, 11, 913-929. 
Parsons, S., Watso, S., Brown, P., Collins, H., Steele, R. (1997). Matrix metalloproteinases. Br J 
Surg, 84, 160-166. 
Petersen, L.C., Lund, L.R., Nielsen, L.S., Danø, K., Skriver, L. (1988). One-chain urokinase-type 
plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic 
activity. Journal of Biological Chemistry, 263, 11189-11195. 
Plumb, J.A., Milroy, R., Kaye, S.B. (1989). Effects of the pH Dependence of 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide-Formazan Absorption on 
Chemosensitivity Determined by a Novel Tetrazolium-based Assay. Cancer Research, 49, 
4435-4440. 
Ponta, H., Sherman, L., Herrlich, P.A. (2003). CD44: From adhesion molecules to signalling 
regulators. Nat Rev Mol Cell Biol, 4, 33-45. 
Qin, H., Sun, Y., Benveniste, E.N. (1999). The Transcription Factors Sp1, Sp3, and AP-2 Are 
Required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells. 
Journal of Biological Chemistry, 274, 29130-29137. 
Rao, J.S., Gondi, C., Chetty, C., Chittivelu, S., Joseph, P.A., Lakka, S.S. (2005). Inhibition of 
invasion, angiogenesis, tumor growth and metastasis by adenovirus-mediated transfer of 
antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther, 4, 
1399-1408. 
Rao, Y.K., Fang, S.-H., Tzeng, Y.-M. (2009). Synthesis and biological evaluation of 3′,4′,5′
-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell 
proliferation. Bioorganic &amp; Medicinal Chemistry, 17, 7909-7914. 
Ravanel, P. (1986). Uncoupling activity of a series of flavones and flavonols on isolated plant 
mitochondria. Phytochemistry, 25, 1015-1020. 
Ravanel, P., Tissut, M., Douce, R. (1980). Uncoupling activities of chalcones and 
dihydrochalcones on isolated mitochondria from potato tubers and mung bean hypocotyls. 
Phytochemistry, 21, 2845-2850. 
Ross, J.S., Fletcher, J.A. (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, 
Predictive Factor, and Target for Therapy. STEM CELLS, 16, 413-428. 
Sabzevari, O., Galati, G., Moridani, M.Y., Siraki, A., O’Brien, P.J. (2004). Molecular cytotoxic 
mechanisms of anticancer hydroxychalcones. Chemico-Biological Interactions, 148, 57-67. 
Sahu, N.K., Balbhadra, S.S., Choudhary, J., Kohli, D.V. (2012). Exploring pharmacological 




Samoszuk, M., Tan, J., Chorn, G. (2005). The chalcone butein from Rhus verniciflua Stokes 
inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC 
Complementary and Alternative Medicine, 5, 5. 
Sartor, L., Pezzato, E., Dell'Aica, I., Caniato, R., Biggin, S., Garbisa, S. (2002). Inhibition of 
matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion 
drug design. Biochem Pharmacol, 64, 229-237. 
Sasaki, C.Y., Barberi, T.J., Ghosh, P., Longo, D.L. (2005). Phosphorylation of RelA/p65 on Serine 
536 Defines an IκBα-independent NF-κB Pathway. Journal of Biological Chemistry, 280, 
34538-34547. 
Sathya, S., Sudhagar, S., Vidhya Priya, M., Bharathi Raja, R., Muthusamy, V.S., Niranjali Devaraj, 
S., Lakshmi, B.S. (2010). 3β-Hydroxylup-20(29)-ene-27,28-dioic acid dimethyl ester, a novel 
natural product from Plumbago zeylanica inhibits the proliferation and migration of 
MDA-MB-231 cells. Chemico-Biological Interactions, 188, 412-420. 
Saydam, G., Aydin, H.H., Sahin, F., Kucukoglu, O., Erciyas, E., Terzioglu, E., Buyukkececi, F., 
Omay, S.B. (2003). Cytotoxic and inhibitory effects of 4,4′-dihydroxy chalcone (RVC-588) on 
proliferation of human leukemic HL-60 cells. Leukemia Research, 27, 57-64. 
Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, 
U., Schmitt, M., Kuhn, W., Lengyel, E. (2001). Increased Expression of Matrix 
Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is 
Associated with Progression from Benign to Advanced Ovarian Cancer. Clinical Cancer 
Research, 7, 2396-2404. 
Schmitt, M., Jänicke, F., Moniwa, N., Chucholowski, N., Pache, L., Graeff, H. (1992). 
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. 
Biol Chem Hoppe Seyler, 373, 611-622. 
Sebti, S.d., Solhy, A., Tahir, R., Boulaajaj, S.d., Mayoral, J.A., Fraile, J.M., Kossir, A., Oumimoun, 
H. (2001). Calcined sodium nitrate/natural phosphate: an extremely active catalyst for the 
easy synthesis of chalcones in heterogeneous media. Tetrahedron Letters, 42, 7953-7955. 
Shamamian, P., Schwartz, J.D., Pocock, B.J.Z., Monea, S., Whiting, D., Marcus, S.G., Mignatti, P. 
(2001). Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and 
proteinase-3: A role for inflammatory cells in tumor invasion and angiogenesis. Journal of 
Cellular Physiology, 189, 197-206. 
Shaulian, E., Karin, M. (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol, 4, 
E131-E136. 
Sheela, S., Barrett, J.C. (1985). Degradation of type IV collagen by neoplastic human skin 
fibroblasts. Carcinogenesis, 6, 173-179. 
Shi, M.-D., Lin, H.-H., Chiang, T.-A., Tsai, L.-Y., Tsai, S.-M., Lee, Y.-C., Chen, J.-H. (2009). 
Andrographolide could inhibit human colorectal carcinoma Lovo cells migration and invasion 
via down-regulation of MMP-7 expression. Chemico-Biological Interactions, 180, 344-352. 
Shibata, S., Inoue, H., Iwata, S., Ma, R., Yu, L., Ueyama, H., Takayasu, J., Hasegawa, T., Tokuda, 
H., Nishino, A., Nishino, H., Iwashima, A. (1991). Inhibitory Effects of Licochalcone A Isolated 
from Glycyrrhiza inflata Root on Inflammatory Ear Edema and Tumour Promotion in Mice. 




Shimao, Y., Nabeshima, K., Inoue, T., Koono, M. (1999). TPA-enhanced motility and invasion in 
a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: selective 
role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC downregulation 
and antisense oligonucleotides treatment. Clin Exp Metastasis, 17, 351-360. 
Siegel, R., Naishadham, D., Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for 
Clinicians, 62, 10-29. 
Sliva, D., English, D., Lyons, D., Lloyd Jr, F.P. (2002a). Protein Kinase C Induces Motility of 
Breast Cancers by Upregulating Secretion of Urokinase-Type Plasminogen Activator through 
Activation of AP-1 and NF-κB. Biochemical and Biophysical Research Communications, 290, 
552-557. 
Sliva, D., Rizzo, M.T., English, D. (2002b). Phosphatidylinositol 3-Kinase and NF-κB Regulate 
Motility of Invasive MDA-MB-231 Human Breast Cancer Cells by the Secretion of 
Urokinase-type Plasminogen Activator. Journal of Biological Chemistry, 277, 3150-3157. 
Slivova, V., Zaloga, G., DeMichele, S.J., Mukerji, P., Huang, Y.-S., Siddiqui, R., Harvey, K., 
Valachovicova, T., Sliva, D. (2005). Green Tea Polyphenols Modulate Secretion of Urokinase 
Plasminogen Activator (uPA) and Inhibit Invasive Behavior of Breast Cancer Cells. Nutrition 
and Cancer, 52, 66-73. 
Solomon, V.R., Lee, H. (2012). Anti-breast cancer activity of heteroaryl chalcone derivatives. 
Biomedicine &amp; Pharmacotherapy, 66, 213-220. 
Sorsa, T., Salo, T., Koivunen, E., Tyynelä, J., Konttinen, Y.T., Bergmann, U., Tuuttila, A., Niemi, E., 
Teronen, O., Heikkilä, P., Tschesche, H., Leinonen, J., Osman, S., Stenman, U.-H. (1997). 
Activation of Type IV Procollagenases by Human Tumor-associated Trypsin-2. Journal of 
Biological Chemistry, 272, 21067-21074. 
Sovak, M.A., Bellas, R.E., Kim, D.W., Zanieski, G.J., Rogers, A.E., Traish, A.M., Sonenshein, G.E. 
(1997). Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. 
J clin Invest, 100, 2952-2960. 
Stamenkovic, I. (2000). Matrix metalloproteinases in tumor invasion and metastasis. Seminars 
in Cancer Biology, 10, 415-433. 
Steeg, P.S., Theodorescu, D. (2008). Metastasis: a therapeutic target for cancer. Nat Clin Prac 
Oncol, 5, 206-219. 
Stein, B., Baldwin, A.S., Ballard, D.W.J., Greene, W.C., Angel, P., Herrlich, P. (1993). 
Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated 
biological function. EMBO J, 12, 3879-3891. 
Stevens, J.F., Miranda, C.L., Frei, B., Buhler, D.R. (2003). Inhibition of Peroxynitrite-Mediated 
LDL Oxidation by Prenylated Flavonoids:   The α,β-Unsaturated Keto Functionality of 
2‘-Hydroxychalcones as a Novel Antioxidant Pharmacophore. Chemical Research in Toxicology, 
16, 1277-1286. 
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., 
Rehm, T., Mühlhahn, P., Schumacher, R., Hesse, F., Kaluza, B., Voelter, W., Engh, R.A., Holak, 
T.A. (2001). Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein 
MDM2 and p53†. Biochemistry, 40, 336-344. 
Stuelten, C.H., Byfield, S.D., Arany, P.R., Karpova, T.S., Stetler-Stevenson, W.G., Roberts, A.B. 
(2005). Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of 




Surh, Y.-J., Chun, K.-S. (2007). Cancer chemopreventive effects of curcumin. 
Szliszka, E., Czuba, Z., Mazur, B., Paradysz, A., Krol, W. (2010). Chalcones and 
dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules, 15, 
5336-5353. 
Tabata, K., Motani, K., Takayanagi, N., Nishimura, R., Asami, S., Kimura, Y., Ukiya, M., 
Hasegawa, D., Akihisa, T., Suzuki, T. (2005). Xanthoangelol, a major chalcone constituent of 
Angelica keiskei, induces apoptosis in neuroblastoma and leukemia cells. Bio Pharm Bull, 28, 
1404-1407. 
Tak, P.P., Firestein, G.S. (2001). NF-κB: a key role in inflammatory diseases. The Journal of 
Clinical Investigation, 107, 7-11. 
Tang, Y., Li, X., Liu, Z., Simoneau, A.R., Xie, J., Zi, X. (2010). Flavokawain B, a kava chalcone, 
induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen 
receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. 
International Journal of Cancer, 127, 1758-1768. 
Templeton, N.S., Brown, P.D., Levy, A.T., Margulies, I.M.K., Liotta, L.A., Stetler-Stevenson, W.G. 
(1990). Cloning and Characterization of Human Tumor Cell Interstitial Collagenase. Cancer 
Research, 50, 5431-5437. 
Thiery, J.P., Sleeman, J.P. (2006). Complex networks orchestrate epithelial-mesenchymal 
transitions. Nat Rev Mol Cell Biol, 7, 131-142. 
Toth, M., Bernardo, M.M., Gervasi, D.C., Soloway, P.D., Wang, Z., Bigg, H.F., Overall, C.M., 
DeClerck, Y.A., Tschesche, H., Cher, M.L., Brown, S., Mobashery, S., Fridman, R. (2000). Tissue 
Inhibitor of Metalloproteinase (TIMP)-2 Acts Synergistically with Synthetic Matrix 
Metalloproteinase (MMP) Inhibitors but Not with TIMP-4 to Enhance the (Membrane Type 
1)-MMP-dependent Activation of Pro-MMP-2. Journal of Biological Chemistry, 275, 
41415-41423. 
Toth, M., Chvyrkova, I., Bernardo, M.M., Hernandez-Barrantes, S., Fridman, R. (2003). 
Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma 
membranes. Biochemical and Biophysical Research Communications, 308, 386-395. 
Toth, M., Gervasi, D.C., Fridman, R. (1997). Phorbol Ester-induced Cell Surface Association of 
Matrix Metalloproteinase-9 in Human MCF10A Breast Epithelial Cells. Cancer Research, 57, 
3159-3167. 
Ueno, H., Nakamura, H., Inoue, M., Imai, K., Noguchi, M., Sato, H., Seiki, M., Okada, Y. (1997). 
Expression and Tissue Localization of Membrane-Types 1, 2, and 3 Matrix Metalloproteinases 
in Human Invasive Breast Carcinomas. Cancer Research, 57, 2055-2060. 
Van den Steen, P., Dubois, B., Nelissen, I., Rudd, P., Dwek, R., Opdenakker, G. (2002). 
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). 
Crit Rev Biochem Mol Biol, 37, 375-536. 
Vanhoecke, B., Derycke, L., Van Marck, V., Depypere, H., De Keukeleire, D., Bracke, M. (2005). 
Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus 
L.) and beer. International Journal of Cancer, 117, 889-895. 
Vargo-Gogola, T., Rosen, J.M. (2007). Modelling breast cancer: one size does not fit all. Nat 
Rev Cancer, 7, 659-672. 
Viatour, P., Merville, M.-P., Bours, V., Chariot, A. (2005). Phosphorylation of NF-κB and IκB 




Vincenti, M., Brinckerhoff, C. (2002). Transcriptional regulation of collagenase (MMP-1, 
MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of 
gene-specific transcription factors. Arthritis Res, 4, 157 - 164. 
Wang, F.-q., So, J., Reierstad, S., Fishman, D.A. (2005). Matrilysin (MMP-7) promotes invasion 
of ovarian cancer cells by activation of progelatinase. International Journal of Cancer, 114, 
19-31. 
Weber, G.F. (2008). Molecular mechanisms of metastasis. Cancer Letters, 270, 181-190. 
Weng, C.-J., Wu, C.-F., Huang, H.-W., Ho, C.-T., Yen, G.-C. (2010). Anti-invasion effects of 
6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells. 
Molecular Nutrition & Food Research, 54, 1618-1627. 
Weniger, J., Chouraqui, J., Zeis, A. (1982). Estrogen secretion by the chick embryo ovary after 
taxomifen treatment. C R Seances Acad Sci III, 294, 1025-1027. 
Westermarck, J., Kahari, V.-M. (1999). Regulation of matrix metalloproteinase expression in 
tumor invasion. The FASEB Journal, 13, 781-792. 
Wyrębska, A., Gach, K., Szemraj, J., Szewczyk, K., Hrabec, E., Koszuk, J., Janecki, T., Janecka, A. 
(2012). Comparison of Anti-Invasive Activity of Parthenolide and 
3-Isopropyl-2-Methyl-4-Methyleneisoxazolidin-5-One (MZ-6) – A New Compound with 
α-Methylene-γ-Lactone Motif – on Two Breast Cancer Cell Lines. Chemical Biology & Drug 
Design, 79, 112-120. 
Xing, R., Rabbani, S. (1996). Overexpression of urokinase receptor in breast cancer cells 
results in increased tumor invasion, growth and metastasis. 1996, 67, 423-429. 
Yamashita, K., Azumano, I., Mai, M., Okada, Y. (1998). Expression and tissue localization of 
matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel 
invasion and metastasis. International Journal of Cancer, 79, 187-194. 
Yan, C., Boyd, D.D. (2007). Regulation of matrix metalloproteinase gene expression. Journal of 
Cellular Physiology, 211, 19-26. 
Yao, J., Xiong, S., Klos, K., Nguyen, N., Grijalva, R., Li, P., Yu, D. (2001). Multiple signaling 
pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-b1 in 
human breast cancer cells. Oncogene, 20, 8066-8074. 
Yuan, J., Dutton, C.M., Scully, S.P. (2005). RNAi mediated MMP-1 silencing inhibits human 
chondrosarcoma invasion. Journal of Orthopaedic Research, 23, 1467-1474. 
Zemzoum, I., Kates, R.E., Ross, J.S., Dettmar, P., Dutta, M., Henrichs, C., Yurdseven, S., Höfler, 
H., Kiechle, M., Schmitt, M., Harbeck, N. (2003). Invasion Factors uPA/PAI-1 and HER2 Status 
Provide Independent and Complementary Information on Patient Outcome in Node-Negative 
Breast Cancer. Journal of Clinical Oncology, 21, 1022-1028. 
Zhang, S., Li, Z., Wu, X., Huang, Q., Shen, H., Ong, C. (2006). Methyl-3-indolylacetate inhibits 







Appendix I. Effects of Chalcones and ISL on PMA-induced MMP-9 
expression and secretion level in MCF-7 cells. MCF-7 cells were treated 
with chalcones for 1h, and then challenged with PMA for 20 h. Conditioned 
medium and whole cell lysates were collected and analyzed by gelatin 
zymography and western blotting as described in Methods. β-actin was probed 




Appendix II. Pharmacokinetic profiling of CC7 and CC9. 
While hydroxylated chalcones may be susceptible to in vivo metabolic 
detoxification, methoxylated chalcones may (predictably) possess greater 
metabolic stability. With the goal to develop chalcones with metabolic stability 
for anti- metastatic therapy, the pharmacokinetic profiles of lead methoxylated 
chalcones CC7 and CC9 were assessed in a rat model routinely applied by Dr 
Lin Haishu (Lin and Ho, 2011) (Department of Pharmacy, NUS). A single 
dose of CC7 and CC9 reconstituted in polyethylene glycol 400 (PEG 400) was 
administered to female Sprague-Dawley rats (n = 3) via oral or intravenous 
routes. The plasma levels of CC7 are shown in Figure 1a, while the major 
pharmacokinetic parameters of CC7 are listed in Table 1a. CC7 possessed 
relatively favorable intravenous pharmacokinetics such as abundant plasma 
exposure (AUC0→last), moderate apparent volume of distribution of the central 
compartment (Vc), clearance (Cl), terminal elimination half-life (t1/2 Z) and, 
mean transition time (MTT). In conclusion, its intravenous pharmacokinetic 
profile did not pose hindrance to its potential clinical application(s). When 
CC7 was given through oral gavage, it was absorbed rapidly and the time to 
maximal plasma concentration (tmax) was 15 min. After tmax, the plasma level 
of CC7 declined gradually and was still detectable in plasma 8 h post-dosing. 
The elimination rate was clearly moderate. However, the maximal plasma 




poor oral bioavailability (F). CC9 was found to have an intravenous 
pharmacokinetic profile similar to that of CC7, i.e. abundant plasma exposure 
and moderate Vc, Cl, t1/2 Z and MTT. However, its oral pharmacokinetics was 
more problematic than CC7; it could not be quantified in any post-dosing 
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Figure 1a Plasma pharmacokinetic profile of CC7 
 
Table 1a Pharmacokinetic parameters of CC7* 
Parameters Intravenous (n = 3) Oral  (n = 3) 
Dose (mg/kg) 4 15 




1.40 ± 0.82 
0.135 ± 
0.041 
Cl (ml/min/kg) 31.7 ± 21.1 - 




MTT0→last (min) 141 ± 30 205 ± 10 
Cmax (ng/ml)  54.1  9.6 
tmax (min) - 15   
F (%)  2.57 ± 0.78 
* Reslts were presented as Mean ± SD.   
 
It is generally believed that the oral bioavailability of a given compound is 
governed by its aqueous solubility, membrane permeability and metabolic 
stability (including efflux mechanisms) (Chan and Stewart, 1996; Hurst et al., 
2007). Given that CC7 and CC9 were administered in water-miscible PEG 400 
and they possessed favorable intravenous pharmacokinetic parameters, poor 
solubility and metabolic instability were ruled out as factors contributing to 
their poor oral bioavailability. Membrane permeability may therefore be the 
barrier to their oral bioavailability. Although not prompted by Lipinski Rule of 
Five or its extension (Lipinski et al., 2001; Oprea et al., 2001), the gold 
standard for lead optimization, we hypothesized that the 2-methoxy 
substituent(s) at the aromatic ring of CC7 and CC9 could have contributed to 
poor oral bioavailability. The pharmacokinetic profiles of various stilbenes 
(resveratrol and its natural occurring and/or synthetic analogs) have been 
extensively examined by Dr Lin Haishu (Das et al., 2008; Lin et al., 2010a; 
Lin and Ho, 2009, 2011; Lin et al., 2012; Lin et al., 2010b; Lin et al., 2009; 




found to drop by 7-10 fold in the presence of methoxy substitution at the 
2-position of the aromatic ring (Lin et al., 2010a; Lin et al., 2012; Lin et al., 
2010b; Lin et al., 2010d). As chalcones and stilbenes share structural 
similarities, the structural-pharmacokinetic relationship observed in stilbenes 
may cross-apply to chalcones. Indeed, the oral bioavailability of CC7 and CC9 
was observed to follow such conjecture; CC9 possessed poorer oral 
bioavailability than CC7 as it contains two methoxy groups (refer to Figure 1a 
for structures of CC7 and CC9). The structural-pharmacokinetic relationship 
of chalcones will be further elucidated using analogs with aromatic 
substitution(s) at different position(s). Of note, although it is aimed to develop 
orally-available chalcone(s) for anti-metastasis treatment, poor oral 
bioavailability does not necessarily hinder chalcones’ clinical applications as 
many anti-cancer drugs are delivered via the parenteral route.   
 
